

## RESEARCH ARTICLE

# Hepatic transcript profiling in beef cattle: Effects of rumen-protected niacin supplementation

Gastón F. Alfaro<sup>2</sup>, Valentino Palombo<sup>5</sup>, Mariasilvia D'Andrea<sup>5</sup>, Wenqi Cao<sup>6</sup>, Yue Zhang<sup>6</sup>, Jonathan Beever<sup>1</sup>, Russell B. Muntifering<sup>2,3</sup>, Wilmer J. Pacheco<sup>4</sup>, Soren P. Rodning<sup>2</sup>, Xu Wang<sup>6,7</sup>, Sonia J. Moisa<sup>1\*</sup>

**1** Department of Animal Sciences, University of Tennessee, Knoxville, TN, United States of America, **2** Department of Animal Sciences, Auburn University, Auburn, AL, United States of America, **3** Cooperative Extension Service, University of Kentucky, Kentucky, Lexington, United States of America, **4** Department of Poultry Sciences, Auburn University, Auburn, AL, United States of America, **5** Department of Agricultural, Environmental and Food Sciences, Università degli Studi del Molise, Campobasso, Italy, **6** Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States of America, **7** HudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America

\* [smoisa@utk.edu](mailto:smoisa@utk.edu)



## OPEN ACCESS

**Citation:** Alfaro GF, Palombo V, D'Andrea M, Cao W, Zhang Y, Beever J, et al. (2023) Hepatic transcript profiling in beef cattle: Effects of rumen-protected niacin supplementation. *PLoS ONE* 18(8): e0289409. <https://doi.org/10.1371/journal.pone.0289409>

**Editor:** Juan J. Loor, University of Illinois, UNITED STATES

**Received:** December 1, 2022

**Accepted:** July 18, 2023

**Published:** August 3, 2023

**Copyright:** © 2023 Alfaro et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** The dataset analysed during the current study is available in the NCBI Gene Expression Omnibus <https://www.ncbi.nlm.nih.gov/geo/> under accession number GSE208241.

**Funding:** S.M. is supported by USDA National Institute of Food and Agriculture, Hatch program -Project No. ALA013-1-19058, Alabama Agriculture Experiment Station (AAES) Production Agriculture Research Funding 2019 award, Alabama Cattlemen Association through Alabama State Beef Checkoff

## Abstract

The objective of our study was to assess the effect of rumen-protected niacin supplementation on the transcriptome of liver tissue in growing Angus × Simmental steers and heifers through RNA-seq analysis. Consequently, we wanted to assess the known role of niacin in the physiological processes of vasodilation, detoxification, and immune function in beef hepatic tissue. Normal weaned calves (~8 months old) were provided either a control diet or a diet supplemented with rumen-protected niacin (6 g/hd/d) for a 30-day period, followed by a liver biopsy. We observed a significant list of changes at the transcriptome level due to rumen-protected niacin supplementation. Several metabolic pathways revealed potential positive effects to the animal's liver metabolism due to administration of rumen-protected niacin; for example, a decrease in lipolysis, apoptosis, inflammatory responses, atherosclerosis, oxidative stress, fibrosis, and vasodilation-related pathways. Therefore, results from our study showed that the liver transcriptional machinery switched several metabolic pathways to a condition that could potentially benefit the health status of animals supplemented with rumen-protected niacin. In conclusion, based on the results of our study, we can suggest the utilization of rumen-protected niacin supplementation as a nutritional strategy could improve the health status of growing beef cattle in different beef production stages, such as backgrounding operations or new arrivals to a feedlot.

## Introduction

Niacin, also known as Vitamin B3 or nicotinic acid, is an essential water-soluble vitamin involved in numerous metabolic functions. For example, niacin is part of the cofactors NAD<sup>+</sup> and NADP<sup>+</sup> in the oxidized form and NADH or NADPH in the reduced form and are present

program 2019 award and QualiTech ©. X.W. is supported by an USDA NIFA Hatch project 1018100, an Alabama Agriculture Experiment Station (AAES) Agriculture Research Enhancement, Exploration, and Development (AgR-SEED) award, and a National Science Foundation EPSCoR RII Track-4 award (OIA1928770). W.C. and Y.Z. are supported by the Auburn University Presidential Graduate Research Fellowship and College of Veterinary Medicine Dean's Fellowship. W.C. is also supported by Alabama EPSCoR Graduate Research Scholars Program.

**Competing interests:** The authors have declared that no competing interests exist.

in many important enzymatic pathways across organisms. Enzymes that depend on niacin are numerous and represent an important factor in metabolism in all organisms. For example, NAD<sup>+</sup> participates in approximately 400 reactions, whereas NADP<sup>+</sup> in 30 different reactions [1]. The major function of NAD<sup>+</sup> and NADP<sup>+</sup> is to regulate cellular electron transfer reactions. Thus, NADH and NADPH are strong electron donors, participating in the maintenance of the redox status of the cell [2]. Niacin is present in feedstuff, and it can be synthesized by the ruminal microflora and in the liver from tryptophan [3]. Although, in some cases could be limiting due to the extensive use in lipid, protein, and carbohydrate metabolism as a cofactor. Since B vitamins play important roles as cofactors in lipid, protein, and carbohydrate synthesis, there may exist a need for supplementation, especially when high forage levels are included in the diet, which presents lower niacin concentration compared to concentrate feeds [4]. Niacin could be minimally absorbed at the rumen level because it usually bounds to rumen microbes; however, most of the niacin is absorbed in the small intestine [1]. In order to avoid ruminal degradation, niacin can be supplemented encapsulated in a chemical coat that helps to by-pass the rumen (RPN) [5]. Rumen-protected niacin has been widely used in dairy cattle due to its numerous metabolic advantages, such as its vasodilatory, antioxidative, and antilipolytic effect [6–8]. Positive effects were observed in high-producing dairy cows supplemented with niacin in terms of feed efficiency, fat corrected milk and milk fat [9]. Even though our group investigated the effect of supplementation with RPN on beef cattle consuming endophyte-infected tall fescue on hematological parameters [10], however little information is available about its effect on beef cattle liver transcriptome. Since niacin directly affects lipid metabolism by inhibiting lipolysis, its utilization in growing beef cattle may improve liver health status. Accordingly, research studies have focused on analyzing changes in metabolic pathways in the liver of dairy cattle [11, 12]. Therefore, the objective of our study was to identify changes at the transcript level of liver tissue of growing Angus × Simmental steers and heifers by supplementation with RPN.

## Materials and methods

### Animals and experimental design

All the procedures for our study were conducted following a protocol approved by the Institutional Animal Care and Use Committee of Auburn University (IACUC Protocol # 2019–3484). During the lactation period, animals used in our study were located at the Black Belt Research Center (32°28'16.32"N 87°13'54.12"W, Marion Junction, AL), belonging to Auburn University. At weaning, steers and heifers were relocated to the Beef Evaluation Center, Auburn University, Auburn, AL, due to the accessibility to the Calan gates system (Northwood, NH, USA). A group of 6 Angus × Simmental, weaned steers (n = 4) and heifers (n = 2) with average body weight (BW; 299 ± 7 kg) and age of 7–9 months old were randomly allocated in two groups based on dietary treatment: Rumen-protected niacin (RPN; n = 3), and Control (CTRL; n = 3). There was a steer: heifer ratio of 2:1 in all treatments (e.g., n = 2 steers and 1 heifer per treatment). After a training period of approximately ten days, animals were successfully adapted to Calan gates, utilized for ensuring the administration of RPN daily dosage per head. The diet offered was *ad libitum* Bermudagrass hay combined with a nutritional supplement composed of 1.61 kg of endophyte-free tall fescue seeds, and 1.61 kg of pellets composed of 46.5% ground corn, 46.5% soybean meal, 5% wheat middlings, and 2% soybean oil; and 0.1 kg of molasses per animal per day (S1 Table). The diet was formulated to meet nutrient requirements (NRC, 2016). Rumen-protected niacin (Anevis, QualiTech, Inc., Chaska, MN, 55318) is presented as white shard or chip shaped pellets that contains 70.0 ± 2.0% of Niacin (C<sub>6</sub>H<sub>5</sub>NO<sub>2</sub>) and it was supplemented following the manufacturers

maximum recommended dosage, which is 6 g/hd/d. In the rumen-protected form (ANEVIS), 67% of the niacin is delivered to the small intestine and the availability of the niacin fed is approximately 30% when fed at the maximum recommended dosage according to manufacture recommendation.

### Liver biopsies

Liver samples (0.5–1 g) were obtained 30 days after the beginning of the supplementation with RPN, using a sterilized bone marrow aspiration needle (Monoject™, Dublin, Ireland) [13]. An area surrounding the 11<sup>th</sup> and 13<sup>th</sup> ribs was scanned by ultrasound to identify the optimal area to perform the liver biopsy. Five milliliters of Lidocaine 2% (VetOne®, Boise, ID) were injected in the selected area. The incision on the skin was performed using a sterilized scalpel blade. Each liver sample was rinsed with sterile saline, placed in a sterile 2 mL cryovial, and immediately stored in liquid nitrogen for further transportation and storage at -80°C at the Beef Nutriepigenomics Laboratory of the Department of Animal Sciences, Auburn University until further analysis.

### RNA extraction and library construction

The total RNA of liver samples was extracted using the ZYMO Quick DNA/RNA Miniprep Plus Kit (Zymo Research, CA, Catalog # D7003) with the addition of a DNase digestion incubation time of 15min. For homogenization, tissue samples with DNA/RNA Shield were mechanically homogenized by Qiagen TissueRuptor II (Qiagen, MD). RNA concentrations were measured by Qubit fluorometer 3.0 (Thermo Fisher Scientific, MA) with Qubit RNA BR Assay Kit. All RNA samples showed RIN values greater than 8.0/10.0.

RNA sequencing libraries were constructed using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs, MA) and NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, MA), with a 1500 ng total RNA input. The concentrations and the size distribution of the libraries were checked by the LabChip GX Touch HT machine using the HT DNA NGS 3K Assay (Perkin Elmer, MA). The fragment size of final libraries ranged from 343 to 409 bp. The libraries were individually barcoded and pooled. The libraries were sequenced on an Illumina NovaSeq 6000 instrument to generate 150-nucleotide paired-end reads.

### RNA-seq analysis

A total number of 628,220,974 read pairs were generated for the six transcriptomes, with sequencing yields ranging from 75,864,914 to 108,428,902 reads per sample. The read quality was checked by FastQC v1.5 [14]. Sequencing adapter sequences and low-quality bases were trimmed using Trimmomatic v0.36 [15]. On average, 98.18% of reads survived quality filtering, and these high-quality reads were mapped to the cattle reference genome (GenBank: GCA\_002263795.2) by Tophat-2.1.1 [16, 17]. The average mapping percentage is 86.76% (S2 Table). RNA concentration was  $834.83 \pm 135.26$  ng/uL.

### Differential gene expression analysis

Gene reads counts were performed in three software packages, Cufflinks-2.2.1 [16], Bedtools-2.30.0 [18], and HT-seq [19]. The counts agreed well for > 99% gene models. A manual check was performed for the remaining gene models in Integrative Genomics Viewer to determine the correct counts [20]. DESeq2 package in R were used to normalize read counts and detect differentially expressed genes (DEGs) [21, 22] at a False Discovery Rate (FDR) threshold of

0.05. The log<sub>2</sub> fold change (LogFC) was determined for each gene. The dataset analysed during the current study is available in the NCBI Gene Expression Omnibus <https://www.ncbi.nlm.nih.gov/geo/> under accession number GSE 208241.

### Quantitative reverse-transcription PCR (qRT-PCR) validation of selected DEGs in liver samples

Concentrations of the six liver RNA samples were measured by Qubit 3.0 Fluorometer (Invitrogen, CA). Reverse transcription was carried out using the RevertAid RT kit (Thermo Scientific, MA). The input of 1 µg total RNA template was mixed with 1 µL Random Hexamer primer, 4 µL 5× Reaction Buffer, 1 µL RiboLock RNase Inhibitor (20 U/µL), 2 µL 10 mM dNTP Mix, 1 µL RevertAid RT (200 U/µL) and proper volume of nuclease-free water that raised the total volume to 20 µL. The 20-µL reaction system was incubated for 5 min at 25°C in an Eppendorf Mastercycler Pro Thermal Cyclers (Eppendorf, CT), followed by 60 min at 42°C, and the reaction was terminated by heating at 70°C for 5 min. The product of the first-strand cDNA synthesis was diluted at 1:1 ratio with nuclease-free water before proceeding with qPCR. Gene-specific qPCR primers were designed using Oligo 7.0 (Molecular Biology Insights Inc., CO) and synthesized at Eurofins Genomics (see [S3 Table](#) for primer sequences). Primer specificity was confirmed by the UCSC In-Silico PCR tool. Ten DEGs were selected for qRT-PCR validation based on fold change expression ([S5 Fig](#)). They were divided into four groups depending on their optimal annealing temperature. Real-time quantitative PCR was carried out using the Luna Universal qPCR Master Mix kit (New England BioLabs, MA) on a BioRad CFX Opus 96 thermocycler (Bio-Rad Laboratories, CA) with the following conditions: an initial denaturing step at 95°C for 60 s, followed by 40 cycles of denaturation at 95°C for 15 s and extension at group-specific extension temperature for 30 s. The reaction system was 20 µL in volume, composed of 10 µL Luna Universal qPCR Mix, 0.5 µL gene-specific forward primer, 0.5 µL gene-specific reverse primer, 1 µL pre-diluted cDNA template, and 8 µL nuclease-free water. After PCR amplification, a melting curve was generated by heating from 65 to 95°C with 0.5°C increments, 3 s dwell time. Each sample had two technical replicates per gene. Relative quantification of gene expression was determined by the C<sub>q</sub> values. The results were visualized using R ([S5 Fig](#)).

### Functional annotation of genes

Functional annotation of genes was carried out to gain insight into the underlying biology of the effect of RPN supplementation in the liver. Database for Annotation, Visualization, and Integrated Discovery (DAVID, version 6.8) [23] was used for functional annotation. DAVID assigned genes to pathways as per the Kyoto Encyclopedia of Genes and Genomes (KEGG), and determined enrichment of pathways using Fisher's exact test [24]. In order to account for multiple testing, a Benjamini-Hochberg correction was applied [25]. A list of DEG was generated using FDR < 0.05 as a cutoff value. Pathways were deemed to be significant if they obtained a corrected *P*-value of < 0.05. Pathways specifically addressing human diseases and disorders were not included in further analysis of DAVID identified pathways, as these were not relevant to our study ([Table 1](#)).

### Dynamic impact approach

We utilized the Dynamic Impact Approach (DIA) analysis for estimating the impact and flux of all the manually curated pathways associated with the KEGG database [26]. We defined the term 'impact' as the change in the expression of the genes belonging to a specific pathway due to the supplementation of RPN; and 'flux' as the report of the average direction in the

**Table 1. Summary of flux and impact results identified by the dynamic impact approach (DIA) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways databases analysis of the bovine liver transcriptome of growing beef cattle supplemented with or without RPN.**

KEGG category	KEGG subcategory	Impact	Flux
Global and overview maps	Carbon metabolism	616.741994	-260.7824775
	Metabolic pathways	603.078811	-226.2043279
	Biosynthesis of amino acids	532.488557	-125.1637293
	Biosynthesis of cofactors	494.30856	-195.915676
	Fatty acid metabolism	476.889691	-307.3373675
<b>Metabolism</b>		676.408654	-311.7001188
	Metabolism of Other Amino Acids	1192.1306	-503.980759
	<b>Glycan Biosynthesis and Metabolism</b>	795.436229	-612.5510388
	<b>Lipid Metabolism</b>	704.232381	-549.4342
	Nucleotide Metabolism	653.534701	-334.3243263
	Amino Acid Metabolism	608.296694	-339.4627242
	Carbohydrate Metabolism	570.910956	-190.4287104
	Xenobiotics Biodegradation and Metabolism	509.163269	319.6926251
	Energy Metabolism	465.005066	334.6533257
Genetic Information Processing		680.499913	-206.8360643
	Replication and Repair	812.248268	-343.7425155
	Folding, Sorting and Degradation	657.625796	-201.0044656
	Transcription	615.987249	-159.510865
	Translation	559.854528	-44.25978518
<b>Environmental Information Processing</b>		960.903322	-784.6343456
	<b>Signaling Molecules and Interaction</b>	980.766095	-777.7726574
	<b>Signal Transduction</b>	965.723931	-785.6111315
	<b>Membrane Transport</b>	780.799763	-780.7997628
<b>Cellular Processes</b>		829.272424	-610.1620241
	<b>Cell Motility</b>	1044.29932	-823.5503655
	<b>Cellular community—eukaryotes</b>	1004.97235	-863.5606025
	<b>Transport and Catabolism</b>	765.983572	-486.3004307
	<b>Cell Growth and Death</b>	752.401923	-541.0458678
<b>Organismal Systems</b>		892.634439	-690.5794713
	<b>Aging</b>	1093.99505	-1057.552977
	<b>Immune System</b>	1004.17577	-902.8083205
	<b>Endocrine System</b>	939.544808	-763.9252758
	<b>Digestive System</b>	939.106527	-700.4125486
	<b>Development</b>	869.624754	-688.5287606
	<b>Circulatory System</b>	787.853847	-522.0104134
	Nervous System	744.077123	-419.7460141
	Excretory System	663.718215	-380.9141043
	Environmental Adaptation	574.101607	-111.8413431
	Sensory System	538.302721	-197.7461005

'Impact' represents the change in the expression of the genes belonging to a specific pathway due to the supplementation of RPN; and 'flux' as the report of the average direction in the expression as downregulation, upregulation, or neutral or no change. Flux represents the direction of each category and the corresponding subcategory: green color represents inhibition, whereas red color shows activation. Blue lines show the impact of each category and the corresponding subcategory ( $P$  value < 0.05; FDR < 0.05). Subcategories highlighted in bold met the defined cutoff criteria.

<https://doi.org/10.1371/journal.pone.0289409.t001>

expression as downregulation, upregulation, or neutral or no change. The entire dataset, including Entrez gene IDs, FDR, Fold Change (FC), and  $p$ -values of each treatment group (RPN and CTRL) were uploaded into DIA, and the overall cutoff was applied on FDR and  $p$ -value  $< 0.05$  as the threshold (Table 1). The cutoff criteria for selecting relevant KEGG results for discussion was to consider those KEGG subcategories and KEGG pathways that met two cutoffs: a) having a value higher than 0.6 of the difference between the absolute value of flux and the impact value and, b) having an impact value greater than 50% of the maximum total impact. Almost all representative KEGG categories ('Metabolism', 'Environmental information processing', 'Cellular processes', and 'Organismal system') were impacted by RPN supplementation showing, in general, an inhibition (or down-regulation). The KEGG categories 'Global and overview maps' and 'Genetic Information Processing' did not have any significantly impacted KEGG subcategory according to our established cutoff criteria; therefore, they were not considered in the discussion.

### PANEV visualization analyses

PANEV (Pathway Network Visualizer) v.1.0 is an R (RStudio, Boston, MA) package which utilizes KEGG database to retrieve information about each KEGG pathway. This method helps to visualize the interconnection among key genes and KEGG pathways that were significantly impacted by the treatment applied (S1 to S4 Figs). PANEV analysis was performed as described in a recent publication [27].

## Results

All animals consumed the supplement composed by endophyte-free tall fescue and pellets along the study. Quantitative Reverse-Transcription PCR performed to validate RNA-seq data presented consistency in the level of expression of the analyzed genes (S5 Fig). A list of 1,192 DEGs (1,131 with entrez gene ID available) between animals that received RPN for 30 days and animal's control were obtained ( $FDR \leq 0.05$ ). Overall, our DEG list generated a downregulated expression pattern by DIA [26]. Indeed, except for the 'Energy Metabolism' and 'Xenobiotics Biodegradation and Metabolism' KEGG subcategories, we observed the downregulation of all main KEGG subcategories (Table 1). In brief, the KEGG category "Metabolism" presented an inhibition of the KEGG subcategories 'Lipid Metabolism' and 'Glycan Biosynthesis and Metabolism' (Table 1). Within the 'Glycan Biosynthesis and Metabolism', the 'Other type of O-glycan biosynthesis' KEGG pathway showed an inhibition and within the 'Lipid Metabolism' KEGG subcategory, the 'Arachidonic acid metabolism' KEGG pathway was inhibited as well (Table 2).

The three KEGG subcategories affected by RPN supplementation in the "Environmental information processing" KEGG category were: 'Membrane Transport', 'Signal transduction' and 'Signaling molecules and interaction'. 'Membrane Transport' KEGG subcategory was affected as a whole, but none of its KEGG pathways satisfy our cutoff criteria; therefore, it was not analyzed. In contrast, 'Signal transduction' KEGG subcategory presented the downregulation of the following pathways: 'Jak-STAT signaling pathway', 'Hippo signaling pathway', 'VEGF signaling pathway', 'HIF-1 signaling pathway', 'TNF signaling pathway', 'Hedgehog signaling pathway', 'Apelin signaling pathway', 'Notch signaling pathway', 'FoxO signaling pathway', 'ErbB signaling pathway', 'PI3K-Akt signaling pathway', 'Rap1 signaling pathway', 'cAMP signaling pathway', 'Phospholipase D signaling pathway', 'cGMP-PKG signaling pathway', 'Sphingolipid signaling pathway', 'MAPK signaling pathway', 'mTOR signaling pathway' and, 'Wnt signaling pathway'. Furthermore, 'ECM-receptor interaction' pathway, which



**Table 2. Results of flux and impact uncovered by the Dynamic Impact Approach (DIA) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) ‘Metabolism’ category database analysis of the bovine liver transcriptome of growing beef cattle with or without RPN supplementation.**

KEGG category	KEGG subcategory	KEGG pathway	Impact	Flux
Metabolism	Carbohydrate Metabolism	Inositol phosphate metabolism		
Metabolism	Carbohydrate Metabolism	Glyoxylate and dicarboxylate metabolism		
Metabolism	Energy Metabolism	Oxidative phosphorylation		
<b>Metabolism</b>	<b>Lipid Metabolism</b>	<b>Arachidonic acid metabolism</b>		
Metabolism	Lipid Metabolism	Glycerophospholipid metabolism		
Metabolism	Lipid Metabolism	Glycerolipid metabolism		
Metabolism	Lipid Metabolism	Steroid hormone biosynthesis		
Metabolism	Nucleotide Metabolism	Purine metabolism		
Metabolism	Amino Acid Metabolism	Glycine, serine and threonine metabolism		
Metabolism	Amino Acid Metabolism	Alanine, aspartate and glutamate metabolism		
Metabolism	Amino Acid Metabolism	Arginine and proline metabolism		
Metabolism	Metabolism of Other Amino Acids	Glutathione metabolism		
<b>Metabolism</b>	<b>Glycan Biosynthesis and Metabolism</b>	<b>Other types of O-glycan biosynthesis</b>		
Metabolism	Glycan Biosynthesis and Metabolism	Glycosaminoglycan biosynthesis—chondroitin sulfate / dermatan sulfate		
Metabolism	Glycan Biosynthesis and Metabolism	N-Glycan biosynthesis		
Metabolism	Xenobiotics Biodegradation and Metabolism	Metabolism of xenobiotics by cytochrome P450		
Metabolism	Xenobiotics Biodegradation and Metabolism	Drug metabolism—cytochrome P450		

‘Impact’ represents the change in the expression of the genes belonging to a specific pathway due to the supplementation of RPN; and ‘flux’ as the report of the average direction in the expression as downregulation, upregulation, or neutral or no change. Flux represents the direction of each subcategory belonging to ‘Metabolism’ KEGG category: green color represents inhibition, yellow neutrality, whereas red color shows activation. Color intensity depicts flux level. Blue lines show the impact of each category and the corresponding subcategory ( $P$  value < 0.05; FDR < 0.05). Subcategories and pathways highlighted in bold met the defined cutoff criteria.

<https://doi.org/10.1371/journal.pone.0289409.t002>

belongs to “Signaling molecules and interaction” KEGG subcategory, was also downregulated (Table 3).

The significant “Cellular processes” KEGG categories were ‘Cellular community–eukaryotes’, ‘Cell Growth and Death’, ‘Cell motility’, and ‘Transport and catabolism’. The “Cellular community–eukaryotes” KEGG subcategory showed two downregulated KEGG pathways: ‘Signaling pathways regulating pluripotency of stem cells’ and ‘Focal adhesion’. The “Cell Growth and Death” KEGG subcategory presented the downregulation of the ‘Apoptosis’ and ‘Cellular senescence’ KEGG pathways. The KEGG subcategory ‘Transport and catabolism’ had an inhibition of ‘Lysosome’ KEGG pathway (Table 4).

The KEGG subcategories affected by RPN supplementation belonging to “Organismal System” KEGG category were ‘Immune system’, ‘Endocrine system’, ‘Digestive system’, ‘Development’ and ‘Aging’. The ‘Immune system’ KEGG subcategory showed the downregulation of the following KEGG pathways: ‘Fc epsilon RI signaling pathway’, ‘B cell receptor signaling pathway’, ‘Fc gamma R-mediated phagocytosis’, ‘T cell receptor signaling pathway’, ‘Toll-like receptor signaling pathway’, ‘Chemokine signaling pathway’, ‘IL-17 signaling pathway’, ‘RIG-I-like receptor signaling pathway’, ‘Leukocyte transendothelial migration’, ‘Neutrophil extracellular trap formation’, ‘Th17 cell differentiation’ and ‘Platelet activation’. The “Digestive system” KEGG subcategory presented the downregulation of ‘Carbohydrate digestion and absorption’, ‘Protein digestion and absorption’ and ‘Cholesterol metabolism’ KEGG pathways. Furthermore, ‘Prolactin signaling pathway’, ‘GnRH secretion’, ‘Thyroid hormone signaling pathway’, ‘Regulation of lipolysis in adipocytes’, ‘Relaxin signaling pathway’, ‘Growth hormone synthesis, secretion and action’, ‘Adipocytokine signaling pathway’, ‘Progesterone-mediated oocyte maturation’, ‘Parathyroid hormone synthesis, secretion and action’, ‘PPAR

**Table 3. Results of flux and impact uncovered by the Dynamic Impact Approach (DIA) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) ‘Environmental information processing’ pathway database analysis of the bovine liver transcriptome of growing beef cattle supplemented with RPN.**

KEGG category	KEGG subcategory	KEGG pathway	Impact	Flux
Environmental Information Processing	Membrane Transport	ABC transporters		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Jak-STAT signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Hippo signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>VEGF signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>HIF-1 signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>TNF signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Hedgehog signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Apelin signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Notch signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>FoxO signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>ErbB signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>PI3K-Akt signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Rap1 signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>cAMP signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Phospholipase D signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>cGMP-PKG signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Sphingolipid signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>MAPK signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>mTOR signaling pathway</b>		
<b>Environmental Information Processing</b>	<b>Signal Transduction</b>	<b>Wnt signaling pathway</b>		
Environmental Information Processing	Signal Transduction	Ras signaling pathway		
Environmental Information Processing	Signal Transduction	TGF-beta signaling pathway		
Environmental Information Processing	Signal Transduction	NF-kappa B signaling pathway		
Environmental Information Processing	Signal Transduction	AMPK signaling pathway		
Environmental Information Processing	Signal Transduction	Phosphatidylinositol signaling system		
Environmental Information Processing	Signal Transduction	Calcium signaling pathway		
<b>Environmental Information Processing</b>	<b>Signaling Molecules and Interaction</b>	<b>ECM-receptor interaction</b>		
Environmental Information Processing	Signaling Molecules and Interaction	Cytokine-cytokine receptor interaction		
Environmental Information Processing	Signaling Molecules and Interaction	Neuroactive ligand-receptor interaction		

‘Impact’ represents the change in the expression of the genes belonging to a specific pathway due to the supplementation of RPN; and ‘flux’ as the report of the average direction in the expression as downregulation, upregulation, or neutral or no change. Flux represents the direction of each subcategory belonging to ‘Environmental Information Processing’ KEGG category: green color represents inhibition, yellow neutrality, whereas red color shows activation. Color intensity depicts flux level. Blue lines show the impact of each category and the corresponding subcategory ( $P$  value < 0.05; FDR < 0.05). Subcategories and pathways highlighted in bold met the defined cutoff criteria.

<https://doi.org/10.1371/journal.pone.0289409.t003>

signaling pathway’, ‘Estrogen signaling pathway’ and, ‘Insulin signaling pathway’ were the downregulated KEGG pathways that belong to “Endocrine system” KEGG subcategory. The KEGG pathways downregulated in “Aging” KEGG subcategory were ‘Longevity regulating pathway—multiple species’ and ‘Longevity regulating pathway’. Finally, the ‘Osteoclast differentiation’ KEGG pathway that belongs to the “Development” KEGG subcategory was inhibited (Table 5).

The “Biological Processes” GO terms affected by RPN supplementation were ‘GO:0006412~translation’ with 29 DEG (FDR = 0.01) and ‘GO:0055114~oxidation-reduction process’ with 41 DEG (FDR = 0.04) (S4 Table). The significant “Cellular Processes” GO terms were ‘GO:0070062~extracellular exosome’ with 188 DEG (FDR =  $3.47 \times 10^{-4}$ ), ‘GO:0005747~mitochondrial respiratory chain complex I’ with 14 DEG (FDR =  $9.45 \times 10^{-4}$ )



**Table 4. Results of flux and impact uncovered by the Dynamic Impact Approach (DIA) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) ‘Cellular Processes’ pathway database analysis of the bovine liver transcriptome of growing beef cattle supplemented with RPN.**

KEGG category	KEGG subcategory	KEGG pathway	Impact	Flux
<b>Cellular Processes</b>	<b>Transport and Catabolism</b>	<b>Lysosome</b>		
Cellular Processes	Transport and Catabolism	Autophagy—animal		
Cellular Processes	Transport and Catabolism	Endocytosis		
Cellular Processes	Transport and Catabolism	Phagosome		
Cellular Processes	Transport and Catabolism	Peroxisome		
Cellular Processes	Transport and Catabolism	Mitophagy—animal		
<b>Cellular Processes</b>	<b>Cell Growth and Death</b>	<b>Apoptosis</b>		
<b>Cellular Processes</b>	<b>Cell Growth and Death</b>	<b>Cellular senescence</b>		
Cellular Processes	Cell Growth and Death	Necroptosis		
Cellular Processes	Cell Growth and Death	p53 signaling pathway		
Cellular Processes	Cell Growth and Death	Cell cycle		
Cellular Processes	Cell Growth and Death	Oocyte meiosis		
Cellular Processes	Cell Growth and Death	Ferroptosis		
<b>Cellular Processes</b>	<b>Cellular community—eukaryotes</b>	<b>Signaling pathways regulating pluripotency of stem cells</b>		
<b>Cellular Processes</b>	<b>Cellular community—eukaryotes</b>	<b>Focal adhesion</b>		
Cellular Processes	Cellular community—eukaryotes	Tight junction		
Cellular Processes	Cellular community—eukaryotes	Gap junction		
<b>Cellular Processes</b>	<b>Cell Motility</b>	<b>Regulation of actin cytoskeleton</b>		

‘Impact’ represents the change in the expression of the genes belonging to a specific pathway due to the supplementation of RPN; and ‘flux’ as the report of the average direction in the expression as downregulation, upregulation, or neutral or no change. Flux represents the direction of each subcategory belonging to ‘Cellular Processes’ KEGG category: green color represents inhibition, yellow neutrality, whereas red color shows activation. Color intensity depicts flux level. Blue lines show the impact of each category and the corresponding subcategory ( $P$  value < 0.05; FDR < 0.05). Subcategories and pathways highlighted in bold met the defined cutoff criteria.

<https://doi.org/10.1371/journal.pone.0289409.t004>

and ‘GO:0016020~membrane’ with 90 DEG (FDR = 0.001) (S5 Table). Finally, the significant “Molecular Function” GO terms were ‘GO:0003735~structural constituent of ribosome’ with 34 DEG (FDR = 0.001) and ‘GO:0044822~poly(A) RNA binding’ with 85 DEG (FDR = 0.008) (S6 Table).

## Discussion

### KEGG pathways

**Metabolism.** Arachidonic acid, a  $\omega$ -6 polyunsaturated fatty acid, is present in the cytosol of the cells in a close spatial relationship with the endoplasmic reticulum membrane. This location allows arachidonic acid to interact with proteins involved in phospholipid synthesis [28]. The downregulation of “arachidonic acid metabolism” pathway could be in accordance with previous evidence showing the inhibitory effect of niacin on lipolysis, specifically of reduced secretion of VLDL molecules in humans [29]. One example of lipolysis disturbance could be explained the downregulation of 85 kDa calcium-independent phospholipase A2 gene (*PLA2G6*, logFC = -3.29; FDR = 0.04) in our study. The *PLA2G6* gene plays a significant role in phospholipid remodeling through catalysis of glycerophospholipid into arachidonic acid and a 2-lysophospholipid [30]. Since lipid accumulation in liver is detrimental, niacin supplementation has been utilized in humans as a pharmacological tool to decrease the flux of lipids from adipose tissue in order to reduce fatty liver conditions [31]; nevertheless, we did not measure the concentration of lipids in hepatic cells. Even though hepatic lipid accumulation does not represent a problem in growing beef cattle, RPN supplementation may improve liver health status by preventing hepatic lipid accumulation [32].

**Table 5. Results of flux and impact uncovered by the Dynamic Impact Approach (DIA) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) ‘Organismal Systems’ pathway database analysis of the bovine liver transcriptome of growing beef cattle supplemented with RPN.**

KEGG category	KEGG subcategory	KEGG pathway	Impact	Flux
Organismal Systems	Immune System	Fc epsilon RI signaling pathway		
Organismal Systems	Immune System	B cell receptor signaling pathway		
Organismal Systems	Immune System	Fc gamma R-mediated phagocytosis		
Organismal Systems	Immune System	T cell receptor signaling pathway		
Organismal Systems	Immune System	Toll-like receptor signaling pathway		
Organismal Systems	Immune System	Chemokine signaling pathway		
Organismal Systems	Immune System	IL-17 signaling pathway		
Organismal Systems	Immune System	RIG-I-like receptor signaling pathway		
Organismal Systems	Immune System	Leukocyte transendothelial migration		
Organismal Systems	Immune System	Neutrophil extracellular trap formation		
Organismal Systems	Immune System	Th17 cell differentiation		
Organismal Systems	Immune System	Platelet activation		
Organismal Systems	Immune System	NOD-like receptor signaling pathway		
Organismal Systems	Immune System	Th1 and Th2 cell differentiation		
Organismal Systems	Immune System	Complement and coagulation cascades		
Organismal Systems	Immune System	Antigen processing and presentation		
Organismal Systems	Endocrine System	Prolactin signaling pathway		
Organismal Systems	Endocrine System	GnRH secretion		
Organismal Systems	Endocrine System	Thyroid hormone signaling pathway		
Organismal Systems	Endocrine System	Regulation of lipolysis in adipocytes		
Organismal Systems	Endocrine System	Relaxin signaling pathway		
Organismal Systems	Endocrine System	Growth hormone synthesis, secretion and action		
Organismal Systems	Endocrine System	Adipocytokine signaling pathway		
Organismal Systems	Endocrine System	Progesterone-mediated oocyte maturation		
Organismal Systems	Endocrine System	Parathyroid hormone synthesis, secretion and action		
Organismal Systems	Endocrine System	PPAR signaling pathway		
Organismal Systems	Endocrine System	Estrogen signaling pathway		
Organismal Systems	Endocrine System	Insulin signaling pathway		
Organismal Systems	Endocrine System	Glucagon signaling pathway		
Organismal Systems	Endocrine System	Melanogenesis		
Organismal Systems	Endocrine System	GnRH signaling pathway		
Organismal Systems	Endocrine System	Oxytocin signaling pathway		
Organismal Systems	Endocrine System	Renin secretion		
Organismal Systems	Endocrine System	Thyroid hormone synthesis		
Organismal Systems	Endocrine System	Cortisol synthesis and secretion		
Organismal Systems	Endocrine System	Insulin secretion		
Organismal Systems	Endocrine System	Ovarian steroidogenesis		
Organismal Systems	Endocrine System	Aldosterone synthesis and secretion		
Organismal Systems	Circulatory System	Adrenergic signaling in cardiomyocytes		
Organismal Systems	Circulatory System	Vascular smooth muscle contraction		
Organismal Systems	Digestive System	Carbohydrate digestion and absorption		
Organismal Systems	Digestive System	Protein digestion and absorption		
Organismal Systems	Digestive System	Cholesterol metabolism		
Organismal Systems	Digestive System	Bile secretion		
Organismal Systems	Digestive System	Pancreatic secretion		
Organismal Systems	Digestive System	Salivary secretion		

(Continued)

Table 5. (Continued)

KEGG category	KEGG subcategory	KEGG pathway	Impact	Flux
Organismal Systems	Digestive System	Gastric acid secretion		
Organismal Systems	Excretory System	Vasopressin-regulated water reabsorption		
Organismal Systems	Excretory System	Endocrine and other factor-regulated calcium reabsorption		
Organismal Systems	Nervous System	Cholinergic synapse		
Organismal Systems	Nervous System	Neurotrophin signaling pathway		
Organismal Systems	Nervous System	Dopaminergic synapse		
Organismal Systems	Nervous System	Long-term depression		
Organismal Systems	Nervous System	Glutamatergic synapse		
Organismal Systems	Nervous System	Synaptic vesicle cycle		
Organismal Systems	Nervous System	Serotonergic synapse		
Organismal Systems	Nervous System	GABAergic synapse		
Organismal Systems	Nervous System	Long-term potentiation		
Organismal Systems	Nervous System	Retrograde endocannabinoid signaling		
Organismal Systems	Sensory System	Inflammatory mediator regulation of TRP channels		
Organismal Systems	Sensory System	Olfactory transduction		
<b>Organismal Systems</b>	<b>Development</b>	<b>Osteoclast differentiation</b>		
Organismal Systems	Development	Axon guidance		
<b>Organismal Systems</b>	<b>Aging</b>	<b>Longevity regulating pathway—multiple species</b>		
<b>Organismal Systems</b>	<b>Aging</b>	<b>Longevity regulating pathway</b>		
Organismal Systems	Environmental Adaptation	Circadian entrainment		
Organismal Systems	Environmental Adaptation	Thermogenesis		

'Impact' represents the change in the expression of the genes belonging to a specific pathway due to the supplementation of RPN; and 'flux' as the report of the average direction in the expression as downregulation, upregulation, or neutral or no change. Flux represents the direction of each subcategory belonging to 'Organismal systems' KEGG category: green color represents inhibition, yellow neutrality, whereas red color shows activation. Color intensity depicts flux level. Blue lines show the impact of each category and the corresponding subcategory ( $P$  value < 0.05; FDR < 0.05). Subcategories and pathways highlighted in bold met our cutoff criteria.

<https://doi.org/10.1371/journal.pone.0289409.t005>

Furthermore, RPN supplementation led to a downregulation in "Other types of O-glycan biosynthesis" pathway. Glycans are defined as carbohydrates linked to proteins, forming glycoproteins; or in lipids, composing glycolipids. Glycans are involved in numerous cellular functions, such as protein folding or signaling, and glycosylation, which occurs as a posttranslational modification of proteins [33]. The glycosylation process starts by the addition of O-linked monosaccharide  $\beta$ -N-acetylglucosamine (GlcNAc) onto serine or threonine hydroxyl groups, which are included in the KEGG pathway "Other types of O-glycan biosynthesis" [34]. In our study, there was a downregulation of polypeptide N-acetylgalactosaminyltransferase 16 (*GALNT16*, logFC = -2.24, FDR = 0.04) and protein O-fucosyltransferase 2 (*POFUT2*, logFC = -2.26, FDR = 0.03), which are responsible for transferring N-acetyl-D-galactosamine and fucose to a serine or threonine residue, respectively [35, 36]. A possible explanation for the inhibition of these genes could be associated with the effect of rumen-protected niacin on hepatic apolipoproteins (apo) B belonging to VLDL and LDL, however, our study did not find significant changes in ApoB expression. It has been previously shown that glycation of human apo-Bs leads to lipidemia [37]. Results from our study demonstrate that RPN supplementation downregulates genes that encode for proteins of glycan biosynthesis, which might suggest that glycation could potentially be inhibited, leading to decreased VLDL and LDL synthesis [38]. Further research may elucidate changes in animal performance and carcass quality due to reduced circulating VLDL and LDL.

**Cellular processes.** The functions of niacin on protection from DNA damage and maintenance of genomic stability have been well investigated in humans and mice [39–41]. A lack of niacin in the human body can delay excision repair, and impair cell cycle arrest and apoptosis as a response to DNA damage [39]. Thus, the alteration of cellular senescence and apoptosis pathways in our results is not surprising. For example, studies have shown that niacin is associated with the alteration of apoptosis-inducing factor (AIF) translocation and apoptosis process in a caspase activation independent way, due to changes in poly (ADP-ribose) polymerase-1 (*PARP-1*) activity [41]. Another study in diabetic mice found that niacin can decrease the high glucose-induced reactive oxidative stress, cell apoptosis and senescence of endothelial progenitor cell in mice [41]. The downregulation in ‘Cell growth and death’ KEGG category occurred from the downregulation of cellular senescence and apoptosis pathways in our results and supports the previous findings of niacin functions.

As for the other significant pathways involved in cellular processes, it is worth mentioning the downregulation of cell motility and cell community KEGG categories, which mainly rely on the downregulation of the “regulation of actin cytoskeleton” pathway and “focal adhesion” pathway. A recent article investigating niacin deficiency and genetic instability also reported alterations of the focal adhesion signaling pathway in niacin-deficient cells in humans [42]. Focal adhesions are involved in various cellular processes, including migration, proliferation, and differentiation [43]. The physical linkage between the extracellular substrate and the actin cytoskeleton at focal adhesions is necessary for cell migration [44]. Our findings suggesting that RPN treatment leads to the downregulation of genes associated with focal adhesion [i.e., actinin (*ACTN4*, logFC = -2.54, FDR = 0.03), filamin (*FLNA*, logFC = -2.54, FDR = 0.03), talin (*TLN1*, logFC = -2.35, FDR = 0.03), and zyxin (*ZYX*, logFC = -2.23, FDR = 0.02)], actin cytoskeleton [i.e., myosin II (*MYH14*, logFC = -5.71, FDR = 0.01) and actin related protein 2/3 complex subunit 1B (*ARPC1B*, logFC = -5.71, FDR = 0.01)] can be explained in a way based on the lipid metabolism regulation function of niacin that we have discussed earlier. Niacin can prevent atherosclerotic cardiovascular disease, and oxidative modification of low-density lipoprotein (oxLDL), which is the major atherogenic modification of low-density lipoprotein [45]. A previous study found that oxLDL induced phosphorylation of focal adhesion kinase (p-FAK) and actin polymerization can be reduced by niacin in mice [46]. Furthermore, the enhancement of FAK phosphorylation and actin polymerization is associated with the inhibition of cell migration [47]. In addition, another study in vascular smooth muscle cells (VSMCs) revealed that niacin attenuated the oxLDL-induced apoptosis by inhibiting the FAK signaling pathway in mice [48]. Finally, the niacin receptor Hydroxycarboxylic acid receptor 2 (*HCA2*) is involved in cellular inflammatory responses. The chemokine-induced migration of macrophages can be inhibited by the niacin-activated *HCA2* [49], which also corresponds to our findings of the downregulation of the immune system.

**Environmental information processing.** Niacin, known to lower cytosolic NADH/NAD<sup>+</sup> ratio, was shown to block the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway which is activated via phosphorylation [50]. The inhibition of the JAK-STAT cascade, which is one of the major inflammatory pathways signaling downstream of cytokines, alters the recruitment of other molecules, or processes downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways. In the liver, *JAK2* is activated by several cytokines and growth factors, including IFN- $\gamma$ , IL-4, IL-6, IL-12, IL-13, growth hormone (GH), and leptin [51]. Signal transducer and transcription activators (STATs) mediate cellular responses to above mentioned chemical signals. Our results suggest that STATs did not experience phosphorylation by JAKs, because STATs dimerization was downregulated; therefore, STAT homodimer translocation to the nucleus could have not occur, inhibiting apoptosis and promoting liver regeneration [52].

Niacin mediates its anti-inflammatory effects via HCA2-dependent mechanisms in monocytes and macrophages [53, 54] by inhibiting their adhesion and accumulation in adipose tissue by oxLDL [55], and in vascular endothelium inhibiting angiotensin II-induced reactive oxygen species (ROS) production (Apelin Signaling Pathway).

Rumen-protected niacin increased the expression of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta (*YWHAB*, logFC = 1.24, FC = 0.03) that belongs to the Hippo signaling pathway which is a critical regulator of liver size [56]. In a previous study, a peak of *YWHAB* expression plays critical roles in the termination of liver regeneration by inhibiting cellular proliferation in male rats [57], this is considered a suggested potential mechanism of *YWHAB* to control liver size. The decrease in organ size could be explained also by the lipolytic effect of niacin in liver adipose tissue content [31]. We were not able to measure liver size in our study. Also, in our study, axin-1 (*AXIN1*, logFC = - 2.19, FC = 0.03) and nucleoside diphosphate kinase 2 (*NKD2*, logFC = - 12.08, FC = 0.005) genes, which are known inhibitors of the  $\beta$ -catenin pathway, were inhibited. The antagonistic effect of *NKD2* on canonical Wnt signaling is achieved by inhibiting the translocation of  $\beta$ -catenin into the nucleus [58], which requires its interaction with *Axin2* [59], since both genes have antiapoptotic effects. The Hippo signaling pathway also presented signs of inhibition of macrophage polarization [60] in the liver through inhibition of *LLGL2* (logFC = -2.16, FDR = 0.01), and *SCRIB* (logFC = -3.08, FDR = 0.02) genes which is a typical reaction during pathological conditions.

The cAMP signaling pathway presented signs of nicotinic acid uptake and transport in hepatic tissue, which appears to be regulated by an intracellular  $\text{Ca}^{2+}$ /calmodulin-mediated pathway in humans [61]. These signs were represented by the activation of ATPase plasma membrane  $\text{Ca}^{2+}$  transporting 1 (*ATP2B1/PMCA*, logFC = 1.71, FDR = 0.01) and calcium/calmodulin dependent protein kinase IV (*CAMK4*, logFC = 1.15, FDR = 0.04), in combination with inhibition of cAMP/PKA/CREB pathway, which is a major regulator of hepatic tissue proliferation and apoptosis [62]. Coincidentally with the WNT/ $\text{Ca}^{2+}$  pathway, the antilipolytic effect of nicotinic acid was evidenced by the Gi-mediated inhibition of adenylate cyclase 1, which inhibits cAMP production, through cholinergic receptor muscarinic 1 (*CHRM1*) activation [63].

The cGMP-PKG signaling pathway is mainly related to vascular contraction and relaxation. A vasodilator effect of RPN supplementation may have been observed during our study by the activation of natriuretic peptide receptor 2 (*NPR2*, logFC = 1.92, FDR = 0.02) and regulator of G protein signaling 2 (*RGS2*, logFC = 1.62, FDR = 0.01); both attenuate the increment of hepatic vascular resistance [64, 65]. Furthermore, myocyte enhancer factor 2 (*MEF2*, logFC = -2.75, FDR = 0.02) was inhibited by RPN supplementation. This gene has a role in the activation of hepatic stellate cells (HSCs), which represents a final common pathway of the hepatic response to liver injury [66]. Nevertheless, caution must be exercised when associating the effects of a physiologic phenomenon from a specific tissue to another, such as vasodilation in vascular tissue to hepatic tissue.

Our results suggested that RPN supplementation could potentially lead to hepatic glucose production *in vivo* through stimulation of a constitutively active Calcium/calmodulin-dependent protein kinase II (*CAMK2D*, logFC = 1.15, FDR = 0.04), which is activated in a calcium- and IP3R-dependent manner by cAMP and glucagon in primary hepatic tissue and by glucagon and fasting *in vivo* (WNT/ $\text{Ca}^{2+}$  pathway) [67]. Furthermore, niacin supplementation produces an inhibition of nuclear factor of activated T-cells, cytoplasmic 4 (*NFATC4*, logFC = -1.79, FDR = 0.02), which induces the expression of cytokine genes in T-cells, especially IL-2 or IL-4 [68].

Matrix metalloproteinase 14 (*MMP-14*, logFC = -3.51, FDR = 0.01) is associated with the degradation of several adhesion molecules, including fibronectin [69] which is the main component of the hepatic extracellular matrix. Particularly, *MMP14* participates in the remodeling of the extracellular matrix which could be harmful to the liver tissue by producing accumulation of extracellular matrix leading to scar tissue formation [69]. Genes that belong to the TNF signaling pathway suggested that RPN supplementation could potentially have a beneficial effect on this process because it reduces ECM deposition through inhibition of the fibrogenic cytokine transforming growth factor  $\beta$  1 (*TGF- $\beta$ 1*, logFC = -5.32, FDR = 0.04) [70]. This statement can be supported by preliminary studies using pharmacologically relevant niacin concentrations to prevent stellate cell fibrosis (collagen type 1 inhibition) induced by *TGF- $\beta$ 1* or oxidative stress mediator hydrogen peroxide ( $H_2O_2$ ), a major physiological stimulator of liver fibrosis [71].

Healthy adult hepatic tissue do not express Hedgehog ligands [72]. Hedgehog ligands undergo complicated posttranslational modifications that result in lipid attachment and multimerization within structure called exosomes in vertebrates [73]. Exosomes carry cargos, including lipid, RNA, and proteins, and play important roles in regulating various biological processes. The inhibition of genes that plays a role in the regulation of endosome-to-lysosome trafficking (i.e., *MEGF8*, logFC = -6.87, FDR = 0.01; *MGRN1*, logFC = -2.44, FDR = 0.01), which are connected to a key transmembrane protein involved in cell-cell communication system called smoothened (Smo). Smoothened is critical for embryonic development and adult tissue homeostasis in vertebrates [74].

Our results also suggest that RPN supplementation activates presenilin-2 (*PSEN2*, logFC = 1.51, FDR = 0.04), which is thought to regulate cell differentiation and survival [75], and inhibited *Deltex 2* (*DTX2*, logFC = -1.89, FDR = 0.03), which is closely involved in cell growth, differentiation, apoptosis, as well as intracellular signal transduction by modulating the Notch signaling pathway [76].

Rumen-protected niacin supplementation produced an inhibition of the Phospholipase D (*PLD*) KEGG pathway. This was the clearest sign of the well-known vasodilator effect of niacin. Briefly, angiotensinogen (*AGT*, logFC = -1.94, FDR = 0.04), which causes vasoconstriction and regulates blood pressure was inhibited by RPN supplementation. Phospholipase C beta 2 (*PLCB2*, logFC = 1.44, FDR = 0.02) catalyzes the hydrolysis of 1-phosphatidylinositol 4,5-bisphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This enzyme regulates the function of the endothelial barrier through intracellular signaling downstream of G protein-coupled receptors [77]. IP3 pathway stimulates sarcoplasmic reticulum release of calcium and activates protein kinase C (PK-C) via the formation of diacylglycerol (DAG), which stimulates contraction [78]. Therefore, upon niacin activation, *GPR109A* (also known as *HCAR2*) couples to a G(i) protein and inhibits adenylate cyclase activity (*ADCY5*, logFC = -3.83, FDR = 0.02) [79], leading to inhibition of liberation of free fatty acid and stimulating vasodilation by inhibiting *AGT*.

Niacin influenced VEGF signaling pathway by causing an inhibition on cell migration through actin reorganization and cell proliferation through the MAPK signaling pathway. A previous study showed that niacin interferes with the signaling cascade of chemoattractants in macrophages. More specifically, niacin might be inhibiting chemoattractant receptor activation that triggers actin cytoskeleton reorganization to form lamellipodia at the leading edge of macrophages. These are clear signs of the inhibitory effect of niacin on chemoattractant-induced cell migration [49] that leads to the macrophage proinflammatory responses of niacin that may contribute as a valuable therapeutic target.

Oxygen-sensing pathways, including the NOTCH-[80], PI3K-AKT-mTOR-[81], MAPK14-[81] and HIF1 $\alpha$ -dependent pathways [82] have hypoxia-induced responses. Amongst these



pathways, the best investigated oxygen responsive factor is the transcription factor hypoxia-inducible factor 1 $\alpha$  (*HIF1A*). In our study, RPN supplementation caused an inhibition of inflammation (*ITGB4*, logFC = -5.72, FDR = 0.01) and increased activation of angiogenesis (*TEK*, logFC = 1.29, FDR = 0.04) observed in the HIF1 pathway. TEK receptor tyrosine kinase (*TEK*) is an inducible early response gene involved in hepatic tissue proliferation and liver regeneration [83].

Furthermore, the FOXO signaling pathway was downregulated, potentially inhibiting oxidative stress resistance and DNA repair (*GADD45*, logFC = -2.63, FDR = 0.02), glucose metabolism (*G6PD*, logFC = -5.36, FDR = 0.01) and immunoregulation (*KLF2*, logFC = -4.17, FDR = 0.03). In contrast, one of the autophagy-related genes was activated (*GABARAP*, logFC = 1.61, FDR = 0.005). Briefly, *GADD45* overexpression has been implicated in stress signaling in response to physiological or environmental stressors, which results in cell cycle arrest, DNA repair, cell survival and senescence, or apoptosis [84]. Glucose-6-phosphate dehydrogenase (*G6PD*), plays an important role in the production of NADPH and restoring the intracellular redox state in the setting of increased oxidant stress [85]. Although, the precise role of niacin on these processes needs to be elucidated. Furthermore, niacin-mediated inactivation of flow-induced transcription factor Krüppel-like factor 2 (*KLF2*) in endothelial cells results in reduced liver damage in mice [86]. Finally, autophagy is a lysosome-mediated catabolic process that targets cytosolic components to lysosomes to be degraded for the purposes of maintaining cellular homeostasis and supplying substrates for energy generation [87]. Dysregulation of autophagy is observed in animal models of diet-induced obesity, oxidative stress, and metabolic syndrome [88]. Our study showed potential signs of activation of this process due to the upregulation of *GABARAP*, which is responsible for the autophagy mechanism involving general membrane remodeling [89].

Our results indicate the downregulation of the ERBB signaling pathway (*PAK4*, logFC = -1.95, FDR = 0.03; *ELK1*, logFC = -1.74, FDR = 0.02), cell adhesion (*HRAS*, logFC = -3.66, FDR = 0.01; *ELK1*), protein synthesis (*AKT1/2*, logFC = -3.82, FDR = 0.03 and logFC = -9.36, FDR = 0.004, respectively; *ELK1*; *RPS6KB2*, logFC = -3.77, FDR = 0.008; *EIF4EBP1*, logFC = -2.75, FDR = 0.02), and cell survival (*AKT1/2*; *BAD*, logFC = -1.45, FDR = 0.04) in response to RPN supplementation. Briefly, p21-activated kinases (PAKs) mediate extracellular signals and regulate cell motility and morphology, cytoskeletal remodeling, cell proliferation, and apoptosis [90]. In terms of cell survival, *AKT* functions in an anti-apoptotic manner by directly phosphorylating the pro-apoptotic Bcl-2-associated death promoter (*BAD*) [91]. A prior study has shown that nicotinic acid infusion in rats results in dephosphorylation of *AKT* in insulin-sensitive tissues, such as liver. Furthermore, *AKT*/mTOR signaling pathway activation has a close relation with inflammation. Phosphorylation of *AKT* or *mTOR* can activate *NF- $\kappa$ B*, leading to its nuclear translocation, producing inflammatory cytokines, such as *INF- $\gamma$*  and *TNF- $\alpha$*  [92]. This drives *AKT*/mTOR signaling to be a target of anti-inflammation. Thus, we hypothesized that the mechanism of anti-inflammatory effects of *HCAR2*, activated by RPN supplementation, took place through inhibiting *AKT*/mTOR signaling pathway in mice [93].

*RAP1* acts as a molecular switch that regulates the cell's response (e. g., changes in orientation, cytoskeleton rearrangements) to external stimuli (i.e., mechanotransduction). Within the *RAP1* metabolic pathway, RPN inhibited the expression of guanine nucleotide exchange factor (*VAV2*, logFC = -4.45, FDR = 0.008), which plays an important role in angiogenesis. A previous study showed that niacin inhibits angiogenesis likely through cytoskeleton remodeling in humans [94]. In our study, FERM, ARH/RhoGEF and pleckstrin domain protein 2 (*FARP2*, logFC = -2.68, FDR = 0.02) has been inhibited by RPN. In addition, *FARP2* has a role in the actin cytoskeleton rearrangement of endothelial cells. Furthermore, the binding of integrins to their extracellular ligands is assisted by actin, producing an integrin-actin linkage mediated by

talin 1 [95]. Talin 1 transitions integrins to an active state leading to cell adhesion, migration, or changes in polarity. Our results suggest that niacin also inhibited the conversion of mechanical forces into biochemical signals through this *RAP1* pathway, leading to attenuation of collagen accumulation exerting potential antifibrotic properties of niacin [70].

The sphingolipid signaling pathway shows a clear inhibition of apoptosis through the activation of phospholipase C beta 2 (*PLCB2*, logFC = 1.44, FDR = 0.02) and sphingosine-1-phosphate receptor 5 (*S1PR5*, logFC = 1.08, FDR = 0.04) and the inhibition of cathepsin D (*CTSD*, logFC = -2.47, FDR = 0.01), *AKT*, *MAPK11/15* (logFC = -2.13, FDR = 0.03 and logFC = -5.80, FDR = 0.005, respectively) and, *BCL2* Associated X, Apoptosis Regulator (*BAX*, logFC = -3.26, FDR = 0.01). *PLCB2* regulates the function of the hepatic endothelial barrier and mediates intracellular signaling downstream of G protein-coupled receptors. In previous research, an increase in phospholipase C gamma 2 (*PLCγ2*) mRNA was detected in the late phase of rat liver regeneration [96]. Although, *TNF-α* alone cannot induce apoptosis in normal hepatic tissue, because *TNF-α* also activates antiapoptotic signal pathways. *TNF-α* induces *SIP* generation via sphingosine kinase 2 (*SPHK2*, logFC = -1.92, FDR = 0.03), which activates survival signals such as the PI3K/AKT pathway and protects human hepatic tissue from *TNF-α*-induced apoptosis [97]. Our results suggest that RPN supplementation could inhibit apoptosis in hepatic tissue through the activation of *S1PR5* and the inactivation of TNF receptor superfamily member 1A (*TNFRSF1A*, logFC = -2.23, FDR = 0.03), which provides instructions for making a tumor necrosis factor receptor 1 (*TNFR1*), and *SPHK2* that encodes one of two sphingosine kinase isozymes that catalyze the phosphorylation of sphingosine into sphingosine 1-phosphate (*SIP*). *SIP* mediates many cellular processes, including migration, proliferation, and apoptosis. Cell death mediated by *TNF-α* employs ceramide as an important second messenger. Ceramide is further hydrolyzed by ceramidase to sphingosine, which subsequently is converted to *SIP* by *SPHK2*. The balance between intracellular concentrations of ceramide and *SIP* may be a critical factor in the determination of cell fate, and our results suggest that RPN supplementation drives this reaction to greater *SIP* production leading to cell survival. Although, little is known about the signaling pathways regulated by ceramide in hepatic tissue [97].

## Organismal systems

Niacin is known to inhibit lipolysis [98], in particular a decreased secretion of VLDL particles is traditionally associated with niacin effect [38]. For this reason, it is important to highlight the downregulation of 'Lipid metabolism' in our experiment (S3 Fig), which was mainly relied on the downregulation of 'Glycerolipid metabolism' and 'Glycerophospholipid metabolism' pathways. Within these two pathways we notably detected the downregulation of Lipin 3 (*LPIN3*, logFC = -2.82, FDR = 0.02), diacylglycerol kinase theta (*DGKQ*, logFC = -3.04, FDR = 0.04), monoglyceride lipase (*MGLL*, logFC = -1.92, FDR = 0.02), and phosphatidylethanolamine-N-methyltransferase (*PEMT*, logFC = -4.08, FDR = 0.02) genes. In particular, the *PEMT* downregulation is remarkable, considering that *PEMT* pathway is known to play a role in lipid metabolism by regulating VLDL secretion in mice [99]. Furthermore, the downregulation of 'Regulation of lipolysis in adipocytes' pathway was compatible with the general scenario of lipolysis inhibition. Notably, within the 'Regulation of lipolysis in adipocytes' pathway, we detected the downregulation of protein kinase A, CAMP-activated non-catalytic subunit gamma 1 (*PRKAG1*, logFC = -1.43, FDR = 0.04), which appeared in line with the role of niacin in lipolysis inhibition via reduction of cAMP [98]. Mechanistically, a reduced protein kinase A (*PKA*) activation leads to a less phosphorylation and activation of the lipolytic enzymes [98]. In this regard, it is interesting to note that we detected the upregulation of protein phosphatase

2 regulatory subunit B'epsilon (*PPP2R5E*, logFC = 1.34, FDR = 0.04) which is known to inhibit AMP kinase [100]. Also, the downregulation of acetyl-CoA carboxylase alpha (*ACACA*, logFC = -2.42, FDR = 0.03) is in line within this context, considering its role in lipid metabolism [101]. Within 'Lipid metabolism' KEGG subcategory, we also detected the partial downregulation of 'Steroid hormone biosynthesis' pathway. This downregulation mainly relied on the inhibition of cytochrome P450, family 2, subfamily d, polypeptide 14 (*CYP2D14*, logFC = -2.42, FDR = 0.03), cytochrome P450 family 11 subfamily A member 1 (*CYP11A1*, logFC = -1.77, FDR = 0.04) and cytochrome P450 2D14-like (*MGC127055*, logFC = -2.55, FDR = 0.02). The inhibition of P450 enzymes by nicotinic acid has been long recognized [102]. Cytochromes P450 are a group of heme-thiolate monooxygenases found at highest concentrations in the liver, where are involved in an NADPH-dependent electron transport pathway [103], and oxidize a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics [104]. This was remarkable since niacin, collectively defined as nicotinamide and nicotinic acid [105], is converted to NAD and NADH, which serve not only as electron carriers in the well-known oxidative respiration [106] but are also important for nucleic acids, fatty acids, and cholesterol synthesis [107]. The marked upregulation of 'Oxidative phosphorylation' is consistent with the role of NAD and NADH as electron carriers. Its upregulation mainly relied on the upregulation of a cluster of NADH:ubiquinone oxidoreductase family genes (such as *NDUFA13*, logFC = 2.12, FDR = 0.01; *NDUFB1*, logFC = 1.86, FDR = 0.005, and *NDUFC1*, logFC = 2.23, FDR = 0.004) in our experiment and it is compatible with the niacin effect on boosting mitochondrial biogenesis and respiratory chain activity [108]. The fact that the 'Mitochondrial respiratory chain complex I' GO term resulted statistically significantly enriched in our experiment appeared in line with this (S6 Table).

Collectively, our results suggested from a transcriptomic point of view that niacin reduces hepatic triglyceride synthesis and increases hepatic lipid oxidation [31]. Furthermore, the downregulation of malonyl-CoA decarboxylase (*MLYCD*, logFC = -1.51, FDR = 0.04) and the upregulation of acyl-CoA synthetase long chain family member 4 (*ACSL4*, logFC = 1.52, FDR = 0.02), which are known to play an important role in the control of fatty acid oxidation [109, 110], were compatible with this depicted scenario.

It is also noteworthy to highlight the downregulation of 'Digestive System' KEGG subcategory, mainly relying on the downregulation of 'Cholesterol metabolism', 'Carbohydrate digestion and absorption' and 'Protein digestion and absorption' pathways. In particular, the downregulation of 'Cholesterol metabolism' was compatible with known niacin effect on total cholesterol decreasing [111]. Within this pathway we notably detected the downregulation of Apolipoprotein E (*APOE*, logFC = -4.93, FDR = 0.01), which is involved in many steps in lipid and lipoprotein homeostasis, for the triglyceride-rich lipoproteins and for HDL [112]. High expression levels of hepatic apoE are traditionally associated with an increase in VLDL triglyceride secretion [113]; thus, its downregulation appeared in line with the well documented effect of niacin in decreasing of hepatic synthesis of triglycerides and VLDL particles [114].

In this general context, the downregulation of 'Bile secretion' pathway seemed inconsistent with the increased biliary secretion traditionally associated with hypocholesterolaemic action of niacin [115]. However, within this pathway, we detected the upregulation of UDP glucuronosyltransferase family 1 member A6 (*UGT1A6*, logFC = 1.25, FDR = 0.03) and 3-hydroxy-3-methylglutaryl-CoA reductase (*HMGCR*, logFC = 1.57, FDR = 0.04) genes. UDP-glucuronosyltransferases (UGTs) are a superfamily of enzymes that generally fulfill detoxification roles, catalyzing the glucuronidation of various exogenous (i.e., environmental toxicants and dietary toxins) as well as endogenous compounds (i.e., bilirubin, steroid hormones, fat soluble vitamins) [116] to increase water-solubility and their elimination from the body in urine or bile [117]. Whereas the upregulation of *HMGCR* was particularly intriguing because of its role as

rate-limiting enzyme for cholesterol synthesis [118]. Indeed, cell culture studies have shown that *AMPK* inactivates *HMGCR*, with a consequent inhibiting effect on cholesterol synthesis [119]. Thus, its upregulation is consistent with the downregulation of *PRKAG1* detected in our experiment. Nevertheless, the possible inhibition effect of nicotinic acid on *HMGCR* activity has been recently proposed [120], thus the role of niacin in regulating *HMGCR*, a key enzyme in cholesterol synthesis, would require further investigations in the light of evidence indicating its role as lipid-lowering molecule [38]. Although the ‘Cholesterol biosynthetic process’ was not enriched, within this BP GO term (S5 Table), along with *HMGCR*, we detected the downregulation of 3 $\beta$ -hydroxysteroid- $\Delta$ 24 reductase (*DHCR24*, logFC = - 3.18, FDR = 0.03), the final enzyme of the cholesterol biosynthetic pathway [121] and *APOA4*, which is known to be involved in cholesterol transport [122]. At the same time, we detected the upregulation of lamin B receptor (*LBR*, logFC = 2.02, FDR = 0.004), whose protein exhibits sterol reductase activity essential for cholesterol biosynthesis [123].

The marked downregulation of ‘Protein digestion and absorption’ pathway was also intriguing. This mainly relied on the downregulation of several genes belonging to the collagen family group, such as *COL4A1* (logFC = - 7.7, FDR = 0.01), *COL6A1* (logFC = - 3.87, FDR = 0.02), *COL6A2* (logFC = - 3.78, FDR = 0.03), *COL18A1* (logFC = - 2.8, FDR = 0.02), which suggested and confirmed the role of niacin as anti-fibrotic agent, as previously shown in human liver [71].

The downregulation of the ‘Immune system’ category was also noteworthy. This result relied on marked downregulation of several pathways, such as ‘Platelet activation’, ‘Chemokine’, ‘Neutrophil extracellular trap formation’, ‘Th17 cell differentiation’ and ‘Fc gamma R-mediated phagocytosis’ pathways. Considering the effects of platelet activation on vasoconstriction [124], our results were compatible with the well documented benefits exerted by niacin on vasodilation [125]. Within ‘Platelet activation’ pathway, we detected the downregulation of *AKT1*, Rho Guanine nucleotide-exchange factor (*ARHGGEF1*, logFC = - 1.67, FDR = 0.04), *TLN1* and the simultaneous upregulation of Prostaglandin-Endoperoxide Synthase 1 (*PTGS1*, logFC = - 1.54, FDR = 0.01). Akt is a serine–threonine kinase that contributes to signaling and activation responses of platelets in mice [126]. Interestingly, *ARHGGEF1* is known to be involved in platelet activity [127]. *TLN1* is required for platelet integrins activation [128]. Furthermore, the upregulation of *PTGS1* is noteworthy considering that prostaglandins induce vasodilation [129] and inhibit the aggregation of platelets [130]. The downregulation of ‘Chemokine signaling’ pathway was consistent with the nicotinic acid effect in the pro-atherogenic chemokines suppression [131, 132]. Furthermore, the downregulation of ‘Th17 cell differentiation’ pathway mainly due to *TGFBI* downregulation was in line with the documented inhibitory effect of niacin on *TGFBI* mRNA expression in hamster [133].

In this context, the downregulation of ‘Relaxin signaling’ pathway was interesting. Although originally known to be present in pregnant individuals, current research identified other biological functions of relaxin in both males and females with physiological roles in vasodilation [134], as shown in humans [135] and rats [136]. This result appeared in contradiction with the expected vasodilator effect of niacin. However, focusing on single DEGs involved in this pathway, we notably detected the downregulation of *TGFBI*. In this regard, the positive interaction of *TGFBI* with endothelin-1, a potent vasoconstrictor secreted by vascular endothelial cells, has been described [137]. Thus, we speculated about the possibility that the downregulation of *TGFBI* might indicate a vasodilation effect of niacin connected with the presumable decrease of endothelin levels. Also, the downregulation of ‘Vascular smooth muscle cells’ pathway was noteworthy, since this could be compatible with a vasodilation state. Within this pathway, we detected the downregulation of *AGT*, a precursor for angiotensin [138], which acts directly on vascular smooth muscle as a potent vasoconstrictor [139].

Overall, the downregulation of ‘Immune system’ KEGG category also supported the notion of a potential anti-inflammatory effect of niacin [140]. The downregulation of *TNFRSF1A*, which is known to be involved in ‘Adipocytokine signaling’ pathway, is in line with this idea. *TNFRSF1A* encodes for a protein called tumor necrosis factor receptor 1 (*TNFR1*) that, when attached to another protein called tumor necrosis factor (TNF), can trigger either inflammation or self-destruction of the cell (apoptosis).

Adipocytokines can influence many bioactivities: notably inflammatory processes, glucose and lipid metabolism [141]. Adiponectin, an important adipocytokine secreted by adipose tissue [142], deserves particular mention since niacin treatment is associated with an increase of adiponectin [143]. Adiponectin plays an important regulatory role in the energy metabolism of cell glucose, sugar, and fatty acids [144, 145], and participates in the regulation of cell proliferation [146], obesity [147], and immune function [148].

The downregulation of ‘Insulin signaling’ pathway was consistent with *AKT1* downregulation [149] and was intriguing. Indeed, the long-term effect of niacin treatment on the impairment of insulin sensitivity has been recently debated [98, 150]. In particular, the role of phosphodiesterase 3B on insulin resistance consequent to a long-term niacin treatment has been proposed [98]. Nevertheless, the downregulation of ‘Insulin signaling’ in our experiment could be compatible with an improved insulin sensitivity. Within ‘Insulin signaling’ pathway, we notably detected the downregulation of *G6PD*, which encodes for a key enzyme involved in the last step of gluconeogenic and glycogenolytic pathways, suggesting gluconeogenesis inhibition. It is well-known that insulin exerts control of gluconeogenesis by acting on the liver, but also by acting on other tissues [151]. For example, in pancreatic  $\alpha$  cells, insulin inhibits the secretion of glucagon, which can indirectly lead to the suppression of hepatic glucose production by reducing hepatic glucagon signaling of mice [152]. This scenario was also supported in our experiment by the downregulation of ‘Glucagon signaling’ pathway, which suggested a normal glucose level and supports the hypothesis of an improved insulin sensitivity. Within this pathway the downregulation of CAMP responsive element binding protein 3 like 3 (*CREB3L3*, logFC = - 1.82, FDR = 0.02) is noteworthy, since CREB is known to be a key activator of the hepatic gluconeogenic gene regulation program [153]. Furthermore, considering that niacin treatment is associated with an increase of adiponectin, an important insulin-sensing hormone, we speculated about the possibility that the downregulation of ‘Insulin signaling’ detected in our experiment could be considered as a feedback effect of adiponectin increase, which was already suggested to play a role in improving insulin sensitivity [138, 154].

Lastly the downregulation of ‘Thyroid hormone’ pathway was compatible with the decrease of thyroid hormone levels associated with niacin supplementation [155]. In this regard, we notably detected the downregulation of thyroid hormone receptor alpha (*THRA*, logFC = - 2.46, FDR = 0.03). Furthermore, within this pathway we also detected the downregulation of Notch Receptor 1 (*NOTCH1*, logFC = - 4.51, FDR = 0.02). The lower expression of *NOTCH1* due to niacin treatment was already reported in an *in vitro* study on niacin effect on vascular inflammation inhibition in cattle [156].

## Conclusion

Rumen-protected niacin supplementation on growing steers and heifers for 30 days after weaning presented a significant list of potential benefits observed at the liver transcriptomics level. Several metabolic pathways revealed positive effects of administration of rumen-protected niacin on beef calves after weaning. The most impacted pathways showed that rumen-protected niacin had a down-regulatory effect on the expression of genes related to lipolysis, apoptosis, inflammatory responses, atherosclerosis, oxidative stress, and fibrosis, and



enhancing vasodilation. Therefore, results from our study could potentially promote supplementation of rumen-protected niacin on beef cattle backgrounding operations or new arrivals to a feedlot, especially during the acclimation period when health status is often compromised. Although, a performance test with a greater number of animals should be conducted in order to confirm these results. Finally, it is important to remark that our study seeks to bring light on the specific role of niacin in growing beef cattle, and caution must be exercised when translating our findings to other species or cattle breeds (i.e., transition dairy cows).

## Supporting information

### S1 Fig.

(TIF)

### S2 Fig.

(TIF)

### S3 Fig.

(TIF)

### S4 Fig.

(TIF)

### S5 Fig.

(TIF)

### S1 Table. Chemical composition of diet fed to growing beef cattle.

(DOCX)

### S2 Table. Summary of RNA-seq yield, quality control, and alignment percentages.

(DOCX)

### S3 Table. List of primers used for qRT-PCR validation assay.

(DOCX)

### S4 Table.

(XLSX)

### S5 Table.

(XLSX)

### S6 Table.

(XLSX)

## Acknowledgments

We want to thank Jamie Yeager (Director, Black Belt Research Center) for providing access to the animals of this study, for assisting the dams during calving, lactation and weaning times and control health and well-being of the cow-calf pairs throughout the study. We would like to thank Robert Britton for this engagement with the research project. We want to thank also Dr. Mullenix and Dr. Dillard for their feedback. Finally, we thank Auburn University Easley Cluster for the computational support of this work.

## Author Contributions

**Conceptualization:** Russell B. Muntifering, Xu Wang, Sonia J. Moisé.



**Data curation:** Valentino Palombo, Mariasilvia D'Andrea, Wenqi Cao, Yue Zhang, Xu Wang.

**Formal analysis:** Gastón F. Alfaro, Valentino Palombo, Mariasilvia D'Andrea, Yue Zhang, Xu Wang.

**Funding acquisition:** Sonia J. Moisés.

**Investigation:** Gastón F. Alfaro, Jonathan Beever, Russell B. Muntifering, Wilmer J. Pacheco, Soren P. Rodning, Sonia J. Moisés.

**Methodology:** Wenqi Cao, Yue Zhang, Jonathan Beever, Russell B. Muntifering, Xu Wang, Sonia J. Moisés.

**Project administration:** Gastón F. Alfaro, Russell B. Muntifering, Soren P. Rodning, Sonia J. Moisés.

**Resources:** Russell B. Muntifering, Wilmer J. Pacheco, Soren P. Rodning, Sonia J. Moisés.

**Software:** Valentino Palombo, Mariasilvia D'Andrea, Xu Wang.

**Supervision:** Jonathan Beever, Sonia J. Moisés.

**Validation:** Wenqi Cao, Yue Zhang, Xu Wang.

**Visualization:** Valentino Palombo, Mariasilvia D'Andrea.

**Writing – original draft:** Gastón F. Alfaro, Valentino Palombo, Mariasilvia D'Andrea, Wenqi Cao, Yue Zhang, Xu Wang, Sonia J. Moisés.

**Writing – review & editing:** Gastón F. Alfaro, Valentino Palombo, Mariasilvia D'Andrea, Jonathan Beever, Wilmer J. Pacheco, Soren P. Rodning, Sonia J. Moisés.

## References

1. Zempleni J, Suttie John, Gregory Jesse, Stover Patrick. Handbook of Vitamins. Routledge CRC Press 2014.
2. Ying W. NAD<sup>+</sup>/NADH and NADP<sup>+</sup>/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences. *Antioxid Redox Signal* 2008; 10:179–206. <https://doi.org/10.1089/ars.2007.1672> PMID: 18020963
3. Fukuwatari T, Shibata K. Nutritional Aspect of Tryptophan Metabolism. *Int J Tryptophan Res IJTR* 2013; 6:3–8. <https://doi.org/10.4137/IJTR.S11588> PMID: 23922498
4. Seck M, Linton JAV, Allen MS, Castagnino DS, Chouinard PY, Girard CL. Apparent ruminal synthesis of B vitamins in lactating dairy cows fed diets with different forage-to-concentrate ratios. *J Dairy Sci* 2017; 100:1914–22. <https://doi.org/10.3168/jds.2016-12111> PMID: 28109593
5. Santschi DE, Berthiaume R, Matte JJ, Mustafa AF, Girard CL. Fate of Supplementary B-Vitamins in the Gastrointestinal Tract of Dairy Cows\*. *J Dairy Sci* 2005; 88:2043–54. [https://doi.org/10.3168/jds.S0022-0302\(05\)72881-2](https://doi.org/10.3168/jds.S0022-0302(05)72881-2) PMID: 15905435
6. Yuan K, Shaver RD, Bertics SJ, Espineira M, Grummer RR. Effect of rumen-protected niacin on lipid metabolism, oxidative stress, and performance of transition dairy cows. *J Dairy Sci* 2012; 95:2673–9. <https://doi.org/10.3168/jds.2011-5096> PMID: 22541495
7. Zimbelman RB, Collier RJ, Bilby TR. Effects of utilizing rumen protected niacin on core body temperature as well as milk production and composition in lactating dairy cows during heat stress. *Anim Feed Sci Technol* 2013; 180:26–33. <https://doi.org/10.1016/j.anifeedsci.2013.01.005>.
8. Ringseis R, Zeitz JO, Weber A, Koch C, Eder K. Hepatic transcript profiling in early-lactation dairy cows fed rumen-protected niacin during the transition from late pregnancy to lactation. *J Dairy Sci* 2019; 102:365–76. <https://doi.org/10.3168/jds.2018-15232> PMID: 30487053
9. Schwab EC, Caraviello DZ, Shaver RD. Review: a meta-analysis of lactation responses to supplemental dietary niacin in dairy cows. *Prof Anim Sci* 2005; 21:239–47. [https://doi.org/10.15232/S1080-7446\(15\)31214-6](https://doi.org/10.15232/S1080-7446(15)31214-6).

10. Alfaro GF, Rodriguez-Zas SL, Southey BR, Muntiferi RB, Rodning SP, Pacheco WJ, et al. Complete Blood Count Analysis on Beef Cattle Exposed to Fescue Toxicity and Rumen-Protected Niacin Supplementation. *Animals* 2021; 11:988. <https://doi.org/10.3390/ani11040988> PMID: 33916070
11. Niehoff I-D, Hüther L, Lebzien P. Niacin for dairy cattle: a review. *Br J Nutr* 2008; 101:5–19. <https://doi.org/10.1017/S0007114508043377> PMID: 18702847
12. Morey SD, Mamedova LK, Anderson DE, Armendariz CK, Titgemeyer EC, Bradford BJ. Effects of encapsulated niacin on metabolism and production of periparturient dairy cows. *J Dairy Sci* 2011; 94:5090–104. <https://doi.org/10.3168/jds.2011-4304> PMID: 21943760
13. Coleman DN, Alharthi A, Lopreiato V, Trevisi E, Miura M, Pan Y-X, et al. Choline supply during negative nutrient balance alters hepatic cystathionine  $\beta$ -synthase, intermediates of the methionine cycle and transsulfuration pathway, and liver function in Holstein cows. *J Dairy Sci* 2019; 102:8319–31. <https://doi.org/10.3168/jds.2019-16406>.
14. Andrews S. Babraham bioinformatics—FastQC a quality control tool for high throughput sequence data 2010. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (accessed August 20, 2021).
15. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinform Oxf Engl* 2014; 30:2114–20. <https://doi.org/10.1093/bioinformatics/btu170> PMID: 24695404
16. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 2012; 7:562–78. <https://doi.org/10.1038/nprot.2012.016> PMID: 22383036
17. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012; 9:357–9. <https://doi.org/10.1038/nmeth.1923> PMID: 22388286
18. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 2010; 26:841–2. <https://doi.org/10.1093/bioinformatics/btq033> PMID: 20110278
19. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 2015; 31:166–9. <https://doi.org/10.1093/bioinformatics/btu638> PMID: 25260700
20. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 2013; 14:178–92. <https://doi.org/10.1093/bib/bbs017> PMID: 22517427
21. Robinson DL, Cafe LM, Greenwood PL. Meat science and muscle biology symposium: developmental programming in cattle: consequences for growth, efficiency, carcass, muscle, and beef quality characteristics. *J Anim Sci* 2013; 91:1428–42. <https://doi.org/10.2527/jas.2012-5799> PMID: 23230118
22. Melchior EA, Smith JK, Schneider LG, Mulliniks JT, Bates GE, Flythe MD, et al. Effects of endophyte-infected tall fescue seed and red clover isoflavones on rumen microbial populations and physiological parameters of beef cattle 1,2. *Transl Anim Sci* 2019; 3:315–28. <https://doi.org/10.1093/tas/txy147>.
23. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. *Genome Biol* 2007; 8:R183. <https://doi.org/10.1186/gb-2007-8-9-r183> PMID: 17784955
24. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000; 28:27–30. <https://doi.org/10.1093/nar/28.1.27> PMID: 10592173
25. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B Methodol* 1995; 57:289–300.
26. Bionaz M, Periasamy K, Rodriguez-Zas SL, Hurley WL, Looor JJ. A novel dynamic impact approach (DIA) for functional analysis of time-course omics studies: validation using the bovine mammary transcriptome. *PloS One* 2012; 7:e32455. <https://doi.org/10.1371/journal.pone.0032455> PMID: 22438877
27. Palombo V, Milanesi M, Sferra G, Capomaccio S, Sgorlon S, D'Andrea M. PANEV: an R package for a pathway-based network visualization. *BMC Bioinformatics* 2020; 21:1–7. <https://doi.org/10.1186/s12859-020-3371-7>.
28. Vance JE. Eukaryotic lipid-biosynthetic enzymes: the same but not the same. *Trends Biochem Sci* 1998; 23:423–8. [https://doi.org/10.1016/s0968-0004\(98\)01297-3](https://doi.org/10.1016/s0968-0004(98)01297-3) PMID: 9852760
29. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man 1. *J Lipid Res* 1981; 22:24–36. [https://doi.org/10.1016/S0022-2275\(20\)34737-4](https://doi.org/10.1016/S0022-2275(20)34737-4).
30. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. *J Lipid Res* 2009; 50:S237–42. <https://doi.org/10.1194/jlr.R800033-JLR200> PMID: 19011112
31. Linder K, Willmann C, Kantartzis K, Machann J, Schick F, Graf M, et al. Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention. *Sci Rep* 2019; 9:1303. <https://doi.org/10.1038/s41598-018-38002-7> PMID: 30718741
32. Kamanna VS, Kashyap ML. Mechanism of Action of Niacin. *Am J Cardiol* 2008; 101:S20–6. <https://doi.org/10.1016/j.amjcard.2008.02.029>.

33. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. *Biochim Biophys Acta BBA—Gen Subj* 1999; 1473:67–95. [https://doi.org/10.1016/s0304-4165\(99\)00170-1](https://doi.org/10.1016/s0304-4165(99)00170-1) PMID: 10580130
34. Steen PV den, Rudd PM, Dwek RA, Opdenakker G. Concepts and Principles of O-Linked Glycosylation. *Crit Rev Biochem Mol Biol* 1998; 33:151–208. <https://doi.org/10.1080/10409239891204198> PMID: 9673446
35. Chen C-I, Keusch JJ, Klein D, Hess D, Hofsteenge J, Gut H. Structure of human POFUT2: insights into thrombospondin type 1 repeat fold and O-fucosylation. *EMBO J* 2012; 31:3183–97. <https://doi.org/10.1038/emboj.2012.143> PMID: 22588082
36. Xu H, Sun J, Zhou L, Du Q-C, Zhu H-Y, Chen Y, et al. Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer. *World J Clin Cases* 2021; 9:10884–98. <https://doi.org/10.12998/wjcc.v9.i35.10884> PMID: 35047599
37. Lyons TJ. Lipoprotein Glycation and Its Metabolic Consequences. *Diabetes* 1992; 41:67–73. <https://doi.org/10.2337/diab.41.2.s67> PMID: 1526339
38. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). *J Nutr Biochem* 2003; 14:298–305. [https://doi.org/10.1016/s0955-2863\(02\)00284-x](https://doi.org/10.1016/s0955-2863(02)00284-x) PMID: 12873710
39. Kirkland JB. Niacin requirements for genomic stability. *Mutat Res Mol Mech Mutagen* 2012; 733:14–20. <https://doi.org/10.1016/j.mrfmmm.2011.11.008> PMID: 22138132
40. Yu S-W, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science* 2002; 297:259–63. <https://doi.org/10.1126/science.1072221> PMID: 12114629
41. Huang P-H, Lin C-P, Wang C-H, Chiang C-H, Tsai H-Y, Chen J-S, et al. Niacin improves ischemia-induced neovascularization in diabetic mice by enhancement of endothelial progenitor cell functions independent of changes in plasma lipids. *Angiogenesis* 2012; 15:377–89. <https://doi.org/10.1007/s10456-012-9267-z> PMID: 22467057
42. Lohani M, Dhasmana A, Haque S, Dar SA, Jawed A, Wahid M, et al. Niacin deficiency modulates genes involved in cancer: Are smokers at higher risk? *J Cell Biochem* 2019; 120:232–42. <https://doi.org/10.1002/jcb.27324> PMID: 30171725
43. Valerie P, Jean-Paul T. Focal adhesions: Structure and dynamics. *Biol Cell* 2000; 92:477–94. [https://doi.org/10.1016/s0248-4900\(00\)01101-1](https://doi.org/10.1016/s0248-4900(00)01101-1) PMID: 11229600
44. Wehrle-Haller B, Imhof BA. The inner lives of focal adhesions. *Trends Cell Biol* 2002; 12:382–9. [https://doi.org/10.1016/s0962-8924\(02\)02321-8](https://doi.org/10.1016/s0962-8924(02)02321-8) PMID: 12191915
45. Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, et al. Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis. *Front Pharmacol* 2021; 2248. <https://doi.org/10.3389/fphar.2020.613780> PMID: 33510639
46. Huang H, Koelle P, Fendler M, Schroettle A, Czihal M, Hoffmann U, et al. Niacin Reverses Migratory Macrophage Foam Cell Arrest Mediated by oxLDL In Vitro. *PLoS One* 2014; 9:e114643. <https://doi.org/10.1371/journal.pone.0114643> PMID: 25521578
47. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. *Mol Cell Biol* 1995; 15:954–63. <https://doi.org/10.1128/MCB.15.2.954> PMID: 7529876
48. Su G, Sun G, Liu H, Shu L, Zhang J, Guo L, et al. Niacin suppresses progression of atherosclerosis by inhibiting vascular inflammation and apoptosis of vascular smooth muscle cells. *Med Sci Monit Int Med J Exp Clin Res* 2015; 21:4081. <https://doi.org/10.12659/msm.895547> PMID: 26712802
49. Shi Y, Lai X, Ye L, Chen K, Cao Z, Gong W, et al. Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization. *Sci Rep* 2017; 7:1–14.
50. Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. *FASEB J* 2005; 19:1–19.
51. Gao B. Cytokines, STATs and liver disease. *Cell Mol Immunol* 2005; 2:92–100. PMID: 16191414
52. Ananthakrishnan R, Hallam K, Li Q, Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. *Vascul Pharmacol* 2005; 43:353–6. <https://doi.org/10.1016/j.vph.2005.08.020> PMID: 16260187
53. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, Wamil M, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. *Arterioscler Thromb Vasc Biol* 2012; 32:669–76. <https://doi.org/10.1161/ATVBAHA.111.241836> PMID: 22267479
54. Lukasova M, Hanson J, Tunaru S, Offermanns S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. *Trends Pharmacol Sci* 2011; 32:700–7. <https://doi.org/10.1016/j.tips.2011.08.002> PMID: 21944259

55. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. *Atherosclerosis* 2009; 202:68–75. <https://doi.org/10.1016/j.atherosclerosis.2008.04.044> PMID: 18550065
56. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. *Curr Biol* 2007; 17:2054–60. <https://doi.org/10.1016/j.cub.2007.10.039> PMID: 17980593
57. Xue D, Xue Y, Niu Z, Guo X, Xu C. Expression analysis on 14-3-3 proteins in regenerative liver following partial hepatectomy. *Genet Mol Biol* 2017; 40:855–9. <https://doi.org/10.1590/1678-4685-GMB-2017-0029> PMID: 29111562
58. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. *Cancer Res* 2011; 71:4028–39.
59. Miller BW, Lau G, Grouios C, Mollica E, Barrios-Rodiles M, Liu Y, et al. Application of an integrated physical and functional screening approach to identify inhibitors of the Wnt pathway. *Mol Syst Biol* 2009; 5:315. <https://doi.org/10.1038/msb.2009.72> PMID: 19888210
60. Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, et al. Macrophage polarization and its role in liver disease. *Front Immunol* 2021:5381. <https://doi.org/10.3389/fimmu.2021.803037> PMID: 34970275
61. Said HM, Nabokina SM, Balamurugan K, Mohammed ZM, Urbina C, Kashyap ML. Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes. *Am J Physiol-Cell Physiol* 2007; 293:C1773–8. <https://doi.org/10.1152/ajpcell.00409.2007> PMID: 17928533
62. Eferl R, Ricci R, Kenner L, Zenz R, David J-P, Rath M, et al. Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. *Cell* 2003; 112:181–92.
63. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. *Trends Pharmacol Sci* 2006; 27:384–90. <https://doi.org/10.1016/j.tips.2006.05.008> PMID: 16766048
64. Osei-Owusu P, Blumer KJ. Regulator of G protein signaling 2: a versatile regulator of vascular function. *Prog Mol Biol Transl Sci* 2015; 133:77–92. <https://doi.org/10.1016/bs.pmbts.2015.02.001> PMID: 26123303
65. Bilzer M, Jaeschke H, Vollmar AM, Paumgartner G, Gerbes AL. Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. *Am J Physiol-Gastrointest Liver Physiol* 1999; 276:G1137–44. <https://doi.org/10.1152/ajpgi.1999.276.5.G1137> PMID: 10330004
66. Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. *Gastroenterology* 2004; 127:1174–88. <https://doi.org/10.1053/j.gastro.2004.07.007> PMID: 15480995
67. Ozcan L, Wong CC, Li G, Xu T, Pajvani U, Park SKR, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. *Cell Metab* 2012; 15:739–51. <https://doi.org/10.1016/j.cmet.2012.03.002> PMID: 22503562
68. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. *Nature* 1994; 369:497–502. <https://doi.org/10.1038/369497a0> PMID: 8202141
69. Geervliet E, Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. *Cells* 2020; 9:1212. <https://doi.org/10.3390/cells9051212> PMID: 32414178
70. Arauz J, Rivera-Espinoza Y, Shibayama M, Favari L, Flores-Beltrán RE, Muriel P. Nicotinic acid prevents experimental liver fibrosis by attenuating the prooxidant process. *Int Immunopharmacol* 2015; 28:244–51. <https://doi.org/10.1016/j.intimp.2015.05.045> PMID: 26093271
71. Kashyap ML, Ganji S, Nakra NK, Kamanna VS. Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug? *J Clin Lipidol* 2019; 13:873–9. <https://doi.org/10.1016/j.jacl.2019.10.006> PMID: 31706905
72. Li L, Zhao J, Zhang Q, Tao Y, Shen C, Li R, et al. Cancer Cell-Derived Exosomes Promote HCC Tumorigenesis Through Hedgehog Pathway. *Front Oncol* 2021; 11:756205. <https://doi.org/10.3389/fonc.2021.756205> PMID: 34692546
73. Ryan KE, Chiang C. Hedgehog secretion and signal transduction in vertebrates. *J Biol Chem* 2012; 287:17905–13. <https://doi.org/10.1074/jbc.R112.356006> PMID: 22474285
74. Kong JH, Siebold C, Rohatgi R. Biochemical mechanisms of vertebrate hedgehog signaling. *Development* 2019; 146. <https://doi.org/10.1242/dev.166892> PMID: 31092502
75. Mattson MP, Chan SL, Camandola S. Presenilin mutations and calcium signaling defects in the nervous and immune systems. *Bioessays* 2001; 23:733–44. <https://doi.org/10.1002/bies.1103> PMID: 11494322

76. Wang L, Sun X, He J, Liu Z. Functions and Molecular Mechanisms of Deltex Family Ubiquitin E3 Ligases in Development and Disease. *Front Cell Dev Biol* 2021; 9:706997. <https://doi.org/10.3389/fcell.2021.706997> PMID: 34513839
77. Tall E, Dorman G, Garcia P, Runnels L, Shah S, Chen J, et al. Phosphoinositide binding specificity among phospholipase C isozymes as determined by photo-cross-linking to novel substrate and product analogs. *Biochem-Ur* 1997; 36:7239–48. <https://doi.org/10.1021/bi9702288> PMID: 9188725
78. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. *Annu Rev Biochem* 2001; 70:281–312. <https://doi.org/10.1146/annurev.biochem.70.1.281> PMID: 11395409
79. Li G, Deng X, Wu C, Zhou Q, Chen L, Shi Y, et al. Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A. *J Biol Chem* 2011; 286:31199–212. <https://doi.org/10.1074/jbc.M111.241372> PMID: 21768093
80. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. *Dev Cell* 2005; 9:617–28. <https://doi.org/10.1016/j.devcel.2005.09.010> PMID: 16256737
81. Ren HX, Accili D, Duan CM. Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways. *P Natl Acad Sci USA* 2010; 107:5857–62. <https://doi.org/10.1073/pnas.0909570107> PMID: 20231451
82. Majmundar AJ, Lee DS, Skuli N, Mesquita RC, Kim MN, Yodh AG, et al. HIF modulation of Wnt signaling regulates skeletal myogenesis in vivo. *Development* 2015; 142:2405–12. <https://doi.org/10.1242/dev.123026> PMID: 26153230
83. Wang S-C, Nakajima Y, Yu Y-L, Xia W, Chen C-T, Yang C-C, et al. Tyrosine phosphorylation controls PCNA function through protein stability. *Nat Cell Biol* 2006; 8:1359–68. <https://doi.org/10.1038/ncb1501> PMID: 17115032
84. Liebermann DA, Hoffman B. Gadd45 in stress signaling. *J Mol Signal* 2008; 3:15. <https://doi.org/10.1186/1750-2187-3-15> PMID: 18789159
85. Ganji SH, Kashyap ML, Kamanna VS. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. *Metabolism* 2015; 64:982–90. <https://doi.org/10.1016/j.metabol.2015.05.002> PMID: 26024755
86. Manavski Y, Abel T, Hu JH, Kleinltzum D, Buchholz CJ, Belz C, et al. Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin A. *P Natl Acad Sci USA* 2017; 114:3993–8. <https://doi.org/10.1073/pnas.1613392114> PMID: 28348240
87. Czaja MJ, Ding W-X, Donohue TM, Friedman SL, Kim J-S, Komatsu M, et al. Functions of autophagy in normal and diseased liver. *Autophagy* 2013; 9:1131–58. <https://doi.org/10.4161/auto.25063> PMID: 23774882
88. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. *Cell Metab* 2010; 11:467–78. <https://doi.org/10.1016/j.cmet.2010.04.005> PMID: 20519119
89. Kumar S, Jia JY, Deretic V. Atg8ylation as a general membrane stress and remodeling response. *Cell Stress* 2021; 5:128–42. <https://doi.org/10.15698/cst2021.09.255> PMID: 34527862
90. Tse EY, Ching YP. The role of p21-activated kinases in hepatocellular carcinoma metastasis. *J Mol Signal* 2014; 9:7. <https://doi.org/10.1186/1750-2187-9-7> PMID: 25093037
91. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers Basel* 2017; 9. <https://doi.org/10.3390/cancers9050052> PMID: 28513565
92. Pratap UP, Sharma HR, Mohanty A, Kale P, Gopinath S, Hima L, et al. Estrogen upregulates inflammatory signals through NF-kappa B, IFN-gamma, and nitric oxide via Akt/mTOR pathway in the lymph node lymphocytes of middle-aged female rats. *Int Immunopharmacol* 2015; 29:591–8.
93. Li ZX, Li XT, Lin SD, Chen YS, Ma SH, Fu YC, et al. Nicotinic Acid Receptor GPR109A Exerts Anti-Inflammatory Effects Through Inhibiting the Akt/mTOR Signaling Pathway in MIN6 Pancreatic beta cells. *Ann Clin Lab Sci* 2017; 47:729–37.
94. Pan L, Yu GF, Chen XJ, Li XQ. Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling. *Organogenesis* 2017; 13:183–91. <https://doi.org/10.1080/15476278.2017.1364829> PMID: 28933636
95. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. *Nat Rev Mol Cell Biol* 2010; 11:633–43. <https://doi.org/10.1038/nrm2957> PMID: 20729930
96. Chen X, Zhu X, Liu Y, Lv Q, Ma J. Silencing of phospholipase C gamma 2 promotes proliferation of rat hepatocytes in vitro. *J Cell Biochem* 2018; 119:4085–96. <https://doi.org/10.1002/jcb.26592> PMID: 29236324



97. Osawa Y, Banno Y, Nagaki M, Brenner DA, Naiki T, Nozawa Y, et al. TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. *J Immunol* 2001; 167:173–80. <https://doi.org/10.4049/jimmunol.167.1.173> PMID: 11418646
98. Heemskerk MM, van den Berg SAA, Pronk ACM, van Klinken J-B, Boon MR, Havekes LM, et al. Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B. *Am J Physiol Endocrinol Metab* 2014; 306:E808–813. <https://doi.org/10.1152/ajpendo.00641.2013> PMID: 24473440
99. Zhao Y, Su B, Jacobs RL, Kennedy B, Francis GA, Waddington E, et al. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice. *Arter Thromb Vasc Biol* 2009; 29:1349–55. <https://doi.org/10.1161/ATVBAHA.109.188672> PMID: 19520976
100. Joseph BK, Liu HY, Francisco J, Pandya D, Donigan M, Gallo-Ebert C, et al. Inhibition of AMP Kinase by the Protein Phosphatase 2A Heterotrimer, PP2A<sup>pp2r2d</sup>. *J Biol Chem* 2015; 290:10588–98. <https://doi.org/10.1074/jbc.M114.626259> PMID: 25694423
101. Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. *Nat Med* 2016; 22:1108–19. <https://doi.org/10.1038/nm.4181> PMID: 27643638
102. Gaudineau C, Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. *Biochem Biophys Res Commun* 2004; 317:950–6. <https://doi.org/10.1016/j.bbrc.2004.03.137> PMID: 15081432
103. Miller WL. Minireview: regulation of steroidogenesis by electron transfer. *Endocrinology* 2005; 146:2544–50. <https://doi.org/10.1210/en.2005-0096> PMID: 15774560
104. Sadler NC, Nandhikonda P, Webb-Robertson BJ, Ansong C, Anderson LN, Smith JN, et al. Hepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human Development. *Drug Metab Dispos* 2016; 44:984–91. <https://doi.org/10.1124/dmd.115.068593> PMID: 27084891
105. Jacobson EL, Kim H, Kim M, Jacobson MK. Niacin: vitamin and antidyslipidemic drug. *Subcell Biochem* 2012; 56:37–47. [https://doi.org/10.1007/978-94-007-2199-9\\_3](https://doi.org/10.1007/978-94-007-2199-9_3) PMID: 22116693
106. Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, Jayasena T, et al. Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. *Antioxid Redox Signal* 2019; 30:251–94. <https://doi.org/10.1089/ars.2017.7269> PMID: 29634344
107. Biller J, Ferro JM. Neurologic aspects of systemic disease, Part III. *Prof Handb Clin Neurol* 2014; 121.
108. Pirinen E, Auranen M, Khan NA, Brilhante V, Urho N, Pessia A, et al. Niacin Cures Systemic NAD(+) Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. *Cell Metab* 2020; 32:144. <https://doi.org/10.1016/j.cmet.2020.05.020> PMID: 32640244
109. Cuthbert KD, Dyck JRB. Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation. *Curr Hypertens Rep* 2005; 7:407–11. <https://doi.org/10.1007/s11906-005-0034-z> PMID: 16386195
110. Coleman RA, Lewin TM, Horn CG, Gonzalez-Baro MR. Do long-chain Acyl-CoA synthetases regulate fatty acid entry into synthetic versus degradative pathways? *J Nutr* 2002; 132:2123–6. <https://doi.org/10.1093/jn/132.8.2123> PMID: 12163649
111. Kuhnast S, Louwe MC, Heemskerk MM, Pieterman EJ, Klinken JB, Berg SAA, et al. Niacin Reduces Atherosclerosis Development in APOE\*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. *Plos One* 2013; 8. <https://doi.org/10.1371/journal.pone.0066467> PMID: 23840481
112. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. *J Lipid Res* 2009; 50:156–61. <https://doi.org/10.1194/jlr.R800058-JLR200> PMID: 19018038
113. Mensenkamp AR, Jong MC, Goor H, Luyn MJA, Bloks V, Havinga R, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. *J Biol Chem* 1999; 274:35711–8. <https://doi.org/10.1074/jbc.274.50.35711> PMID: 10585451
114. Hochholzer W, Berg DD, Giugliano RP. The facts behind niacin. *Ther Adv Cardiovasc Dis* 2011; 5:227–40.
115. Holland RE, Rahman K, Morris AI, Billington D. Effects of niacin on biliary lipid output in the rat. *Biochem Soc Trans* 1993; 21:144.
116. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. *Pharmacol Ther* 2005; 106:97–132. <https://doi.org/10.1016/j.pharmthera.2004.10.013> PMID: 15781124
117. Arbitrio M, Scionti F, Martino MT, Pensabene L, Tassone P, Tagliaferri P. Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters. In: Ed, editor. Elsevier, 2021.



118. Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). *J Biol Chem* 2013; 288:18707–15. <https://doi.org/10.1074/jbc.R113.479808> PMID: 23696639
119. Loh K, Tam S, Murray-Segal L, Huynh K, Meikle PJ, Scott JW, et al. Inhibition of Adenosine Mono-phosphate-Activated Protein Kinase-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholesterolemia and Promotes Hepatic Steatosis and Insulin Resistance. *Hepatology* 2019; 3:84–98. <https://doi.org/10.1002/hep4.1279> PMID: 30619997
120. Moselhy SS, Kamal IH, Kumosani TA, Huwait EA. Possible inhibition of hydroxy methyl glutaryl CoA reductase activity by nicotinic acid and ergosterol: as targeting for hypocholesterolemic action. *Afr Health Sci* 2016; 16:319–24. <https://doi.org/10.4314/ahs.v16i1.42> PMID: 27358648
121. Dai M, Zhu XL, Liu F, Xu QY, Ge QL, Jiang SH, et al. Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma. *Sci Rep* 2017; 7:41404. <https://doi.org/10.1038/srep41404> PMID: 28112250
122. Qu J, Ko CW, Tso P, Bhargava A. Apolipoprotein A-IV: A Multifunctional Protein Involved in Protection against Atherosclerosis and Diabetes. *Cells* 2019; 8. <https://doi.org/10.3390/cells8040319> PMID: 30959835
123. Subramanian G, Chaudhury P, Malu K, Fowler S, Manmode R, Gotur D, et al. Lamin B receptor regulates the growth and maturation of myeloid progenitors via its sterol reductase domain: implications for cholesterol biosynthesis in regulating myelopoiesis. *J Immunol* 2012; 188:85–102. <https://doi.org/10.4049/jimmunol.1003804> PMID: 22140257
124. Golino P, Ashton JH, Buja LM, Rosolowsky M, Taylor AL, McNatt J, et al. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. *Circulation* 1989; 79:154–66. <https://doi.org/10.1161/01.cir.79.1.154> PMID: 2910540
125. Hamilton SJ, Chew GT, Davis TM, Watts GF. Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. *Diab Vasc Res* 2010; 7:296–9. <https://doi.org/10.1177/1479164110376206> PMID: 20667937
126. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. *Blood* 2004; 104:1703–10. <https://doi.org/10.1182/blood-2003-10-3428> PMID: 15105289
127. Comer SP. Turning Platelets Off and On: Role of RhoGAPs and RhoGEFs in Platelet Activity. *Front Cardiovasc Med* 2021; 8:820945. <https://doi.org/10.3389/fcvm.2021.820945> PMID: 35071371
128. Petrich BG, Marchese P, Ruggeri ZM, Spiess S, Weichert RAM, Ye F, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. *J Exp Med* 2007; 204:3103–11. <https://doi.org/10.1084/jem.20071800> PMID: 18086863
129. Murrant CL, Dodd JD, Foster AJ, Inch KA, Muckle FR, Ruiz DA, et al. Prostaglandins induce vasodilatation of the microvasculature during muscle contraction and induce vasodilatation independent of adenosine. *J Physiol* 2014; 592:1267–81. <https://doi.org/10.1113/jphysiol.2013.264259> PMID: 24469074
130. Smith JB. Prostaglandins and platelet aggregation. *Acta Med Scand* 1981; Suppl 651:91–9. <https://doi.org/10.1111/j.0954-6820.1981.tb03638.x> PMID: 7034481
131. Xing XK, Wang H, Zhao L, Bai YX, Xie F, He JJ, et al. Niacin downregulates chemokine (c-c motif) ligand 2 (CCL2) expression and inhibits fat synthesis in rat liver cells. *Trop J Pharm Res* 2020; 19:977–82.
132. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. *Atherosclerosis* 2010; 209:89–95. <https://doi.org/10.1016/j.atherosclerosis.2009.08.045> PMID: 19781706
133. Gurujeyalakshmi G, Hollinger MA, Giri SN. Regulation of transforming growth factor-beta1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis. *Am J Respir Cell Mol Biol* 1998; 18:334–42. <https://doi.org/10.1165/ajrcmb.18.3.2867> PMID: 9490651
134. Skøtt O, Carter AM. Relaxin is a vasodilator hormone. *Am J Physiol-Regul Integr Comp Physiol* 2002; 283:347 8. <https://doi.org/10.1152/ajpregu.00264.2002> PMID: 12121846
135. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. *J Card Fail* 2009; 15:182–90. <https://doi.org/10.1016/j.cardfail.2009.01.008> PMID: 19327619
136. Debrah DO, Conrad KP, Danielson LA, Shroff SG. Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. *J Appl Physiol* 2005; 98:1013–20. <https://doi.org/10.1152/jappphysiol.01083.2004> PMID: 15489259

137. Castanares C, Redondo-Horcajo M, Magan-Marchal N, Lamas S, Rodriguez-Pascual F. Transforming growth factor-beta receptor requirements for the induction of the endothelin-1 gene. *Exp Biol Med* Maywood 2006; 231:700–3. PMID: [16740983](#)
138. Lu H, Cassis LA, Kooi CW, Daugherty A. Structure and functions of angiotensinogen. *Hypertens Res* 2016; 39:492–500. <https://doi.org/10.1038/hr.2016.17> PMID: [26888118](#)
139. Wynne BM, Chiao CW, Webb RC. Vascular Smooth Muscle Cell Signaling Mechanisms for Contraction to Angiotensin II and Endothelin-1. *J Am Soc Hypertens* 2009; 3:84–95. <https://doi.org/10.1016/j.jash.2008.09.002> PMID: [20161229](#)
140. Nakamichi R, Miranda EP, Lobo SM, Tristao VR, Dalboni MA, Quinto BM, et al. Action of nicotinic acid on the reversion of hypoxic-inflammatory link on 3T3-L1 adipocytes. *Lipids Health Dis* 2016; 15:91. <https://doi.org/10.1186/s12944-016-0260-1> PMID: [27164826](#)
141. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. *Clin Chem* 2004; 50:1511–25. <https://doi.org/10.1373/clinchem.2004.032482> PMID: [15265818](#)
142. Sun Y, Xun K, Wang C, Zhao H, Bi H, Chen X, et al. Adiponectin, an unlocking adipocytokine. *Cardiovasc Ther* 2009; 27:59–75. <https://doi.org/10.1111/j.1755-5922.2008.00069.x> PMID: [19207481](#)
143. Wanders D, Graff EC, White BD, Judd RL. Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice. *Plos One* 2013; 8:71285. <https://doi.org/10.1371/journal.pone.0071285> PMID: [23967184](#)
144. Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. *Int J Mol Sci* 2019; 20. <https://doi.org/10.3390/ijms20051190> PMID: [30857216](#)
145. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. *Cell Metab* 2013; 17:779–89. <https://doi.org/10.1016/j.cmet.2013.04.005> PMID: [23663741](#)
146. Wang Y, Lam KSL, Xu JY, Lu G, Xu LY, Cooper GJS, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. *J Biol Chem* 2005; 280:18341–7. <https://doi.org/10.1074/jbc.M501149200> PMID: [15734737](#)
147. Daniele A, Cammarata R, Masullo M, Nerone G, Finamore F, D'Andrea M, et al. Analysis of adiponectin gene and comparison of its expression in two different pig breeds. *Obes Silver Spring* 2008; 16:1869–74. <https://doi.org/10.1038/oby.2008.275> PMID: [18535556](#)
148. Luo Y, Liu M. Adiponectin: a versatile player of innate immunity. *J Mol Cell Biol* 2016; 8:120–8. <https://doi.org/10.1093/jmcb/mjw012> PMID: [26993045](#)
149. Kwon H, Pessin JE. Insulin-mediated PI3K and AKT signaling. In: Wiley LJ, Sons, editors. *The Liver*, 2020, p. 485–95.
150. Montastier E, Beuzelin D, Martins F, Mir L, Marques MA, Thalamas C, et al. Niacin induces miR-502-3p expression which impairs insulin sensitivity in human adipocytes. *Int J Obes* 2019; 43:1485–90. <https://doi.org/10.1038/s41366-018-0260-5> PMID: [30482933](#)
151. Hattang M, Tavares CDJ, Sharabi K, Rines AK, Puigserver P. Insulin regulation of gluconeogenesis. *Ann N Acad Sci* 1411, 2018, p. 21–35. <https://doi.org/10.1111/nyas.13435> PMID: [28868790](#)
152. Ravier M, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. *Diabetes* 2005; 54:1789–97. <https://doi.org/10.2337/diabetes.54.6.1789> PMID: [15919801](#)
153. Oh KJ, Han HS, Kim MJ, Koo SH. CREB and FoxO1: two transcription factors for the regulation of hepatic gluconeogenesis. *BMB Rep* 2013; 46:567–74. <https://doi.org/10.5483/bmbrep.2013.46.12.248> PMID: [24238363](#)
154. Fraterrigo G, Fabbri E, Mittendorfer B, O'Rahilly S, Scherer PE, Patterson BW, et al. Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy 2012.
155. Shakir KMM, Kroll S, Aprill BS, Drake AJ, Eisold JF. Nicotinic-Acid Decreases Serum Thyroid-Hormone Levels While Maintaining a Euthyroid State. *Mayo Clin Proc* 1995; 70:556–8. <https://doi.org/10.4065/70.6.556> PMID: [7776715](#)
156. Rong Y, Zeng M, Guan X, Qu K, Liu J, Zhang J, et al. Association of HSF1 Genetic Variation with Heat Tolerance in Chinese Cattle. *Animals* 2019; 9:1027. <https://doi.org/10.3390/ani9121027> PMID: [31775331](#)